J Wouter Jukema

List of Publications by Year
in descending order

986	91,414	315 138	582 262
papers	citations	h-index	g-index

1056	1056	1056	75507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	13.7	3,823
2	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	13.9	3,337
3	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, The, 2002, 360, 1623-1630.	6.3	3,147
4	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
5	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, The, 2010, 375, 735-742.	6.3	2,064
6	A comprehensive 1000 Genomesâ€“based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	9.4	2,054
7	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	9.4	1,818
8	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	9.4	1,685
9	Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nature Genetics, 2018, 50, 1505-1513.	9.4	1,331
10	Diagnostic Accuracy of 64-Slice Computed Tomography Coronary Angiography. Journal of the American College of Cardiology, 2008, 52, 2135-2144.	1.2	1,136
11	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics, 2018, 50, 524-537.	9.4	1,124
12	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	9.4	1,100
13	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 2018, 50, 1412-1425.	9.4	924
14	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, The, 2012, 379, 1214-1224.	6.3	886
15	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature Genetics, 2012, 44, 659-669.	9.4	762
16	Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nature Genetics, 2012, 44, 991-1005.	9.4	746
17	Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels. Circulation, 1995, 91, 2528-2540.	1.6	718
18	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	13.9	701

#	Article	IF	Citations
19	The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis. New England Journal of Medicine, 1998, 338, 86-93.	13.9	625
20	Association of Cardiometabolic Multimorbidity With Mortality. JAMA - Journal of the American Medical Association, 2015, 314, 52.	3.8	624
21	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	6.3	562
22	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation, 2018, 137, 338-350.	1.6	559
23	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health, 2019, 7, e1332-e1345.	2.9	554
24	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	9.4	552
25	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	13.7	544
26	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
27	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ, The, 2014, 349, g4164-g4164.	3.0	528
28	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	6.3	512
29	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
30	Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nature Genetics, 2017, 49, 403-415.	9.4	492
31	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal, 2021, 42, 2439-2454.	1.0	491
32	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5.8	484
33	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470
34	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	5.8	466
35	Prognostic Value of Multislice Computed Tomography Coronary Angiography in Patients With Known or Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 49, 62-70.	1.2	461
36	Relationship Between Noninvasive Coronary Angiography With Multi-Slice Computed Tomography and Myocardial Perfusion Imaging. Journal of the American College of Cardiology, 2006, 48, 2508-2514.	1.2	441

#	Article	IF	Citations
37	Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	3.0	428
38	Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	13.9	427
39	Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, The, 2008, 371, 1927-1935.	6.3	416
40	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 2016, 7, 10023.	5.8	412
41	Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events. Circulation, 2012, 126, 1040-1049.	1.6	410
42	Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nature Genetics, 2011, 43, 1005-1011.	9.4	403
43	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal, 2007, 154, 221-231.	1.2	390
44	Statins and All-Cause Mortality in High-Risk Primary Prevention. Archives of Internal Medicine, 2010, 170, 1024.	4.3	385
45	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology, 2021, 28, 1279-1289.	0.8	369
46	Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. New England Journal of Medicine, 2017, 376, 2534-2544.	13.9	366
47	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. American Heart Journal, 2014, 168, 682-689.e1.	1.2	365
48	Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and doseâ€“response meta-regression. Europace, 2013, 15, 742-749.	0.7	357
49	Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2012, 307, 2499-506.	3.8	352
50	Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53â€‰949). Molecular Psychiatry, 2015, 20, 183-192.	4.1	344
51	The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021, 53, 840-860.	9.4	341
52	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	1.5	331
53	Statins for Secondary Prevention in Elderly Patients. Journal of the American College of Cardiology, 2008, 51, 37-45.	1.2	326
54	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	2.6	326

#	Article	IF	Citations
55	The design of a prospective study of pravastatin in the elderly at risk (PROSPER). American Journal of Cardiology, 1999, 84, 1192-1197.	0.7	310
56	Prognostic Value of Multislice Computed Tomography and Gated Single-Photon Emission Computed Tomography in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 623-632.	1.2	308
57	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. New England Journal of Medicine, 2017, 376, 1517-1526.	13.9	307
58	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. Circulation, 2017, 135, 2373-2388.	1.6	304
59	Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment. Circulation, 2005, 111, 278-287.	1.6	302
60	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	1.2	296
61	Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nature Communications, 2018, 9, 260.	5.8	295
62	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 2015, 47, 1282-1293.	9.4	294
63	Lipid Treatment Assessment Project 2. Circulation, 2009, 120, 28-34.	1.6	293
64	Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology. FASEB Journal, 2010, 24, 3135-3144.	0.2	287
65	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286
66	Common Genetic Variation inABCA1Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease. Circulation, 2001, 103, 1198-1205.	1.6	280
67	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	9.4	279
68	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 311, 252.	3.8	270
69	Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 99, 1072-1081.	0.7	269
70	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	9.4	261
71	Intravascular Ultrasound Guidance Improves Angiographic and Clinical Outcome of Stent Implantation for Long Coronary Artery Stenoses. Circulation, 2003, 107, 62-67.	1.6	252
72	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250

#	Article	IF	Citations
73	Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. European Heart Journal, 2010, 31, 1172-1180.	1.0	248
74	Reduction in Cardiovascular Events During Pravastatin Therapy. Circulation, 1995, 92, 2419-2425.	1.6	240
75	Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 2010, 257, 85-90.	1.8	238
76	B-Mode Ultrasound Assessment of Pravastatin Treatment Effect on Carotid and Femoral Artery Walls and Its Correlations With Coronary Arteriographic Findings: A Report of the Regression Growth Evaluation Statin Study (REGRESS). Journal of the American College of Cardiology, 1998, 31, 1561-1567.	1.2	236
77	Restenosis after PCI. Part 1: pathophysiology and risk factors. Nature Reviews Cardiology, 2012, 9, 53-62.	6.1	233
78	Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. International Journal of Epidemiology, 2012, 41, 1419-1433.	0.9	230
79	Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. Human Molecular Genetics, 2014, 23, 4420-4432.	1.4	227
80	Vein graft failure: from pathophysiology to clinical outcomes. Nature Reviews Cardiology, 2016, 13, 451-470.	6.1	220
81	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nature Genetics, 2017, 49, 1450-1457.	9.4	218
82	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	5.8	216
83	Diagnostic Accuracy of 64-Slice Multislice Computed Tomography in the Noninvasive Evaluation of Significant Coronary Artery Disease. American Journal of Cardiology, 2006, 98, 145-148.	0.7	215
84	Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. European Heart Journal, 2008, 29, 2373-2381.	1.0	215
85	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836.	1.2	214
86	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
87	High-Sensitivity Cardiac Troponin Concentration and Risk of First-EverÂCardiovascular Outcomes inÂ154,052 Participants. Journal of the American College of Cardiology, 2017, 70, 558-568.	1.2	213
88	Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation, 2003, 107, 2416-2421.	1.6	211
89	Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation, 2004, 110, 1418-1423.	1.6	210
90	KLB is associated with alcohol drinking, and its gene product Î²-Klotho is necessary for FGF21 regulation of alcohol preference. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14372-14377.	3.3	208

#	Article	IF	Citations
91	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
92	Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet, The, 2020, 395, 1374-1381.	6.3	205
93	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. European Heart Journal, 2012, 33, 857-865.	1.0	201
94	Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2552-2559.	1.1	200
95	Lesional Overexpression of Matrix Metalloproteinase-9 Promotes Intraplaque Hemorrhage in Advanced Lesions But Not at Earlier Stages of Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 340-346.	1.1	196
96	Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart, 2009, 95, 715-720.	1.2	196
97	Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. European Heart Journal, 2012, 33, 1007-1016.	1.0	194
98	A Meta-Analysis of Thyroid-Related Traits Reveals Novel Loci and Gender-Specific Differences in the Regulation of Thyroid Function. PLoS Genetics, 2013, 9, e1003266.	1.5	194
99	Identification and systematic annotation of tissue-specific differentially methylated regions using the Illumina 450k array. Epigenetics and Chromatin, 2013, 6, 26.	1.8	192
100	A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. Nature Communications, 2019, 10, 3346.	5.8	188
101	Pathophysiology and treatment of atherosclerosis. Netherlands Heart Journal, 2017, 25, 231-242.	0.3	186
102	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. Circulation, 2014, 130, 1225-1235.	1.6	183
103	Thermolabile Methylenetetrahydrofolate Reductase in Coronary Artery Disease. Circulation, 1997, 96, 2573-2577.	1.6	183
104	Progression of brain atrophy and cognitive decline in diabetes mellitus. Neurology, 2010, 75, 997-1002.	1.5	182
105	Validation and reproducibility of aortic pulse wave velocity as assessed with velocityâ€encoded MRI. Journal of Magnetic Resonance Imaging, 2009, 30, 521-526.	1.9	181
106	Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nature Communications, 2018, 9, 4455.	5.8	181
107	Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1225.	3.8	179
108	Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 852-861.	1.8	178

#	Article	IF	Citations
109	Automatic quantification and characterization of coronary atherosclerosis with computed tomography coronary angiography: cross-correlation with intravascular ultrasound virtual histology. International Journal of Cardiovascular Imaging, 2013, 29, 1177-1190.	0.7	178
110	Drug-eluting stents: results, promises and problems. International Journal of Cardiology, 2005, 99, 9-17.	0.8	176
111	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal, 2017, 38, 2499-2507.	1.0	176
112	Relation of Epicardial Adipose Tissue to Coronary Atherosclerosis. American Journal of Cardiology, 2008, 102, 1602-1607.	0.7	175
113	Diagnostic accuracy of 320-row multidetector computed tomography coronary angiography in the non-invasive evaluation of significant coronary artery disease. European Heart Journal, 2010, 31, 1908-1915.	1.0	173
114	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	13.7	173
115	Noninvasive Evaluation With Multislice Computed Tomography in Suspected Acute Coronary Syndrome. Journal of the American College of Cardiology, 2008, 52, 216-222.	1.2	172
116	Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nature Genetics, 2010, 42, 688-691.	9.4	170
117	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nature Communications, 2017, 8, 14977.	5.8	169
118	Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. PLoS Genetics, 2012, 8, e1002584.	1.5	166
119	The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. European Journal of Epidemiology, 2013, 28, 513-523.	2.5	166
120	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal, 2011, 32, 2541-2554.	1.0	165
121	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. Journal of Lipid Research, 2014, 55, 2103-2112.	2.0	165
122	Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2181-2191.	1.8	164
123	Cardiovascular metabolic syndrome ? an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, Obesity and Metabolism, 2007, 9, 218-232.	2.2	163
124	Multiethnic Genome-Wide Association Study of Cerebral White Matter Hyperintensities on MRI. Circulation: Cardiovascular Genetics, 2015, 8, 398-409.	5.1	162
125	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein inAPOE*3Leiden.CETPMice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2016-2022.	1.1	161
126	Feasibility of assessment of coronary stent patency using 16-slice computed tomography. American Journal of Cardiology, 2004, 94, 427-430.	0.7	159

#	Article	IF	Citations
127	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics Journal, 2012, 12, 233-237.	0.9	158
128	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterolâ€“Lowering Effect in APOE*3-Leiden Transgenic Mice. Circulation, 2003, 108, 1368-1374.	1.6	157
129	â^'455G/A Polymorphism of the Î²-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 265-271.	1.1	155
130	Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. European Heart Journal, 2008, 30, 266-277.	1.0	154
131	Blood lipids influence DNA methylation in circulating cells. Genome Biology, 2016, 17, 138.	3.8	154
132	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	1.2	154
133	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993â€“2003. Atherosclerosis, 2006, 187, 415-422.	0.4	153
134	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications, 2016, 7, 10494.	5.8	153
135	Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome. Journal of the American College of Cardiology, 2008, 51, 618-626.	1.2	148
136	Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease. European Heart Journal, 2009, 30, 2622-2629.	1.0	147
137	Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy. Journal of the American College of Cardiology, 2010, 55, 1611-1618.	1.2	147
138	A single dose of erythropoietin in ST-elevation myocardial infarction. European Heart Journal, 2010, 31, 2593-2600.	1.0	144
139	Common C-to-T Substitution at Position â^'480 of the Hepatic Lipase Promoter Associated With a Lowered Lipase Activity in Coronary Artery Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2837-2842.	1.1	143
140	Epigenetics in atherosclerosis and inflammation. Journal of Cellular and Molecular Medicine, 2010, 14, 1225-1240.	1.6	143
141	Lipoprotein Lipase S447X. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1236-1245.	1.1	140
142	Role of the Apolipoprotein Bâ€“Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Caseâ€“Control Analysis in EPIC-Norfolk. Annals of Internal Medicine, 2007, 146, 640.	2.0	140
143	The Controversies of Statin Therapy. Journal of the American College of Cardiology, 2012, 60, 875-881.	1.2	140
144	Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris. Circulation, 1996, 94, 1503-1505.	1.6	140

#	Article	IF	Citations
145	Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart, 2008, 94, 290-295.	1.2	139
146	Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis, 2011, 106, 1-19.	1.8	139
147	Aging, Retirement, and Changes in Physical Activity: Prospective Cohort Findings from the GLOBE Study. American Journal of Epidemiology, 2007, 165, 1356-1363.	1.6	137
148	Usefulness of 64-Slice Multislice Computed Tomography Coronary Angiography to Assess In-Stent Restenosis. Journal of the American College of Cardiology, 2007, 49, 2204-2210.	1.2	137
149	Secondary prevention with folic acid: effects on clinical outcomes. Journal of the American College of Cardiology, 2003, 41, 2105-2113.	1.2	136
150	Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. American Journal of Cardiology, 1999, 83, 852-856.	0.7	135
151	Testing cognitive function in elderly populations: the PROSPER study. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 385-389.	0.9	134
152	Head-to-Head Comparison of Coronary Plaque Evaluation Between Multislice Computed Tomography and Intravascular Ultrasound Radiofrequency Data Analysis. JACC: Cardiovascular Interventions, 2008, 1, 176-182.	1.1	134
153	GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Molecular Psychiatry, 2016, 21, 189-197.	4.1	134
154	Value of Fast Gradient Echo Magnetic Resonance Angiography as an Adjunct to Coronary Arteriography in Detecting and Confirming the Course of Clinically Significant Coronary Artery Anomalies. American Journal of Cardiology, 1997, 79, 773-776.	0.7	133
155	Detection of Vein Graft Disease Using High-Resolution Magnetic Resonance Angiography. Circulation, 2002, 105, 328-333.	1.6	133
156	Brown adipose tissue volume in healthy lean south Asian adults compared with white Caucasians: a prospective, case-controlled observational study. Lancet Diabetes and Endocrinology,the, 2014, 2, 210-217.	5.5	131
157	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	1.2	131
158	Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2016, 15, 695-707.	4.9	130
159	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. JAMA Cardiology, 2018, 3, 806.	3.0	129
160	Impact of Simultaneous Pancreas and Kidney Transplantation on Progression of Coronary Atherosclerosis in Patients With End-Stage Renal Failure due to Type 1 Diabetes. Diabetes Care, 2002, 25, 906-911.	4.3	128
161	Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease. Circulation, 2013, 128, 1310-1324.	1.6	128
162	Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study. BMJ, The, 2013, 347, f4600-f4600.	3.0	127

#	Article	IF	Citations
163	Novel Genetic Markers Associate With Atrial Fibrillation Risk in Europeans and Japanese. Journal of the American College of Cardiology, 2014, 63, 1200-1210.	1.2	127
164	Noninvasive coronary imaging and assessment of left ventricular function using 16-slice computed tomography. American Journal of Cardiology, 2005, 95, 571-574.	0.7	123
165	Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. Hypertension, 2017, 70, .	1.3	123
166	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. Diabetes, 2016, 65, 2448-2460.	0.3	122
167	CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms. Circulation, 2007, 116, 1931-1941.	1.6	121
168	Association Between Apolipoprotein E₄ and Cognitive Decline in Elderly Adults. Journal of the American Geriatrics Society, 2007, 55, 1777-1785.	1.3	120
169	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRAâ€¢CER) trial: study design and rationale. American Heart Journal, 2009, 158, 327-334.e4.	1.2	120
170	Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 93-99.	1.8	120
171	GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nature Communications, 2018, 9, 5141.	5.8	119
172	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nature Communications, 2017, 8, 910.	5.8	118
173	Seven Lipoprotein Lipase Gene Polymorphisms, Lipid Fractions, and Coronary Disease: A HuGE Association Review and Meta-Analysis. American Journal of Epidemiology, 2008, 168, 1233-1246.	1.6	117
174	Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology, 2019, 93, e2257-e2271.	1.5	117
175	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	1.0	117
176	MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. American Heart Journal, 2007, 153, 14.e1-14.e11.	1.2	116
177	Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice. Circulation, 2001, 103, 1778-1786.	1.6	115
178	No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1635-1640.	1.1	115
179	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	1.2	115
180	Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C->A polymorphism and a novel promoter variant are independently associated with CETP concentration. Human Molecular Genetics, 2003, 12, 111-123.	1.4	114

#	Article	IF	Citations
181	Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 2005, 112, 3058-3065.	1.6	113
182	52 Genetic Loci Influencing MyocardialÂMass. Journal of the American College of Cardiology, 2016, 68, 1435-1448.	1.2	113
183	C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 2007, 115, 981-989.	1.6	112
184	Cerebral Microbleeds Are Predictive of Mortality in the Elderly. Stroke, 2011, 42, 638-644.	1.0	110
185	Usefulness of dynamic multislice computed tomography of left ventricular function in unstable angina pectoris and comparison with echocardiography. American Journal of Cardiology, 2002, 90, 1157-1160.	0.7	109
186	Cystatin C and Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 934-945.	1.2	109
187	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
188	Body fat distribution, in particular visceral fat, is associated with cardiometabolic risk factors in obese women. PLoS ONE, 2017, 12, e0185403.	1.1	107
189	Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H755-H763.	1.5	106
190	Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabetic Medicine, 2008, 25, 277-281.	1.2	106
191	Effect of Smoking on Blood Pressure and Resting Heart Rate. Circulation: Cardiovascular Genetics, 2015, 8, 832-841.	5.1	105
192	Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). European Journal of Clinical Investigation, 2004, 34, 21-28.	1.7	104
193	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation, 2020, 141, 1608-1617.	1.6	104
194	The Asp ₉ Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis. Circulation, 1996, 94, 1913-1918.	1.6	103
195	Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation, 2019, 139, 620-635.	1.6	102
196	T-cell co-stimulation by CD28â€“CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. International Journal of Cardiology, 2013, 168, 1965-1974.	0.8	101
197	Stabilization of atherosclerotic plaques: an update. European Heart Journal, 2013, 34, 3251-3258.	1.0	101
198	Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 839-846.	1.1	100

#	Article	IF	Citations
199	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	5.8	100
200	Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2013, 112, 1867-1872.	0.7	98
201	CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European Heart Journal, 2008, 29, 2792-2799.	1.0	97
202	Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). Journal of Lipid Research, 2012, 53, 1000-1011.	2.0	97
203	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	1.0	97
204	ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clinical Genetics, 2002, 61, 115-125.	1.0	95
205	Overexpression of IL-18 Decreases Intimal Collagen Content and Promotes a Vulnerable Plaque Phenotype in Apolipoprotein-Eâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2313-2319.	1.1	95
206	Circulating interleukinâ€6 concentration and cognitive decline in old age: the <scp>PROSPER</scp> study. Journal of Internal Medicine, 2013, 274, 77-85.	2.7	95
207	Leukocyte telomere length associates with prospective mortality independent of immune-related parameters and known genetic markers. International Journal of Epidemiology, 2014, 43, 878-886.	0.9	95
208	The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart, 2014, 100, 685-690.	1.2	95
209	Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care, 2004, 27, 2887-2892.	4.3	94
210	Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease. Archives of Internal Medicine, 2004, 164, 40.	4.3	93
211	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal, 2011, 32, 336-344.	1.0	93
212	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nature Genetics, 2020, 52, 1314-1332.	9.4	91
213	Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report from the regression growth evaluation statin study. American Journal of Cardiology, 1995, 76, 40C-46C.	0.7	90
214	Comprehensive assessment of spotty calcifications on computed tomography angiography: Comparison to plaque characteristics on intravascular ultrasound with radiofrequency backscatter analysis. Journal of Nuclear Cardiology, 2011, 18, 893-903.	1.4	90
215	Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation, 2008, 117, 2515-2522.	1.6	89
216	Diagnostic Accuracy of 320-Row Multidetector Computed Tomography Coronary Angiography to Noninvasively Assess In-Stent Restenosis. Investigative Radiology, 2010, 45, 331-340.	3.5	89

#	Article	IF	Citations
217	Cerebral small vessel disease genomics and its implications across the lifespan. Nature Communications, 2020, 11, 6285.	5.8	89
218	Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography. American Heart Journal, 2005, 150, 775-781.	1.2	87
219	Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. Nature Communications, 2016, 7, 10846.	5.8	87
220	Genetic Risk Prediction of Atrial Fibrillation. Circulation, 2017, 135, 1311-1320.	1.6	87
221	Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 2021, 12, 24.	5.8	87
222	Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events?. PLoS Medicine, 2009, 6, e1000099.	3.9	87
223	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research, 2007, 48, 1763-1771.	2.0	86
224	Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility. Circulation, 2010, 122, 470-477.	1.6	86
225	Quaking, an RNA-Binding Protein, Is a Critical Regulator of Vascular Smooth Muscle Cell Phenotype. Circulation Research, 2013, 113, 1065-1075.	2.0	86
226	Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB Journal, 2014, 28, 5361-5375.	0.2	85
227	Value of Magnetic Resonance Imaging for the Noninvasive Detection of Stenosis in Coronary Artery Bypass Grafts and Recipient Coronary Arteries. Circulation, 2003, 107, 1502-1508.	1.6	84
228	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
229	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	5.8	84
230	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 2019, 140, 2054-2062.	1.6	83
231	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	4.1	83
232	BMP7 Activates Brown Adipose Tissue and Reduces Diet-Induced Obesity Only at Subthermoneutrality. PLoS ONE, 2013, 8, e74083.	1.1	82
233	Circulating Interleukin-10 and Risk of Cardiovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2338-2344.	1.1	81
234	Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation, 2019, 139, 2628-2638.	1.6	81

#	Article	IF	Citations
235	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 727-739.	0.2	80
236	Evidence for a Synergistic Effect of Calcium Channel Blockers With Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis in Symptomatic Patients With Normal to Moderately Raised Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 425-430.	1.1	78
237	Not Acute but Chronic Hypertriglyceridemia Is Associated With Impaired Endothelium-Dependent Vasodilation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 744-750.	1.1	78
238	Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2008, 1, 192-201.	1.1	78
239	Assessment of global and regional left ventricular function and volumes with 64-slice MSCT: A comparison with 2D echocardiography. Journal of Nuclear Cardiology, 2006, 13, 480-487.	1.4	76
240	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis, 2008, 197, 57-63.	0.4	76
241	Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPICâ€Norfolk Prospective Population Study. Journal of Internal Medicine, 2007, 262, 678-689.	2.7	74
242	Incremental value of subclinical left ventricular systolic dysfunction for the identification of patients with obstructive coronary artery disease. American Heart Journal, 2010, 159, 148-157.	1.2	74
243	Annexin A5 Therapy Attenuates Vascular Inflammation and Remodeling and Improves Endothelial Function in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 95-101.	1.1	74
244	A metabolomic profile is associated with the risk of incident coronary heart disease. American Heart Journal, 2014, 168, 45-52.e7.	1.2	74
245	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	2.9	74
246	Tumor necrosis factorâ€Î± plays an important role in restenosis development. FASEB Journal, 2005, 19, 1998-2004.	0.2	73
247	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics, 2016, 25, 358-370.	1.4	73
248	Global and regional left ventricular function assessment with 16-detector row CT: Comparison with echocardiography and cardiovascular magnetic resonance. European Journal of Echocardiography, 2006, 7, 308-314.	2.3	72
249	Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis, 2008, 200, 109-114.	0.4	72
250	Leptin Predicts Diabetes but Not Cardiovascular Disease. Diabetes Care, 2009, 32, 308-310.	4.3	72
251	Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 54, 1238-1245.	1.2	72
252	The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. Journal of the American College of Cardiology, 2004, 43, 854-857.	1.2	71

#	Article	IF	Citations
253	PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nature Communications, 2018, 9, 2904.	5.8	71
254	Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities. Stroke, 2020, 51, 2111-2121.	1.0	71
255	Raman Spectroscopic Evaluation of the Effects of Diet and Lipid-Lowering Therapy on Atherosclerotic Plaque Development in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1630-1635.	1.1	70
256	Coronary collaterals improve prognosis in patients with ischemic heart disease. International Journal of Cardiology, 2009, 132, 257-262.	0.8	70
257	Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics. Nature Methods, 2014, 11, 868-874.	9.0	70
258	Different manifestations of coronary artery disease by stress SPECT myocardial perfusion imaging, coronary calcium scoring, and multislice CT coronary angiography in asymptomatic patients with type 2 diabetes mellitus. Journal of Nuclear Cardiology, 2008, 15, 503-509.	1.4	69
259	Positive Remodeling on Coronary Computed Tomography as a Marker for Plaque Vulnerability on Virtual Histology Intravascular Ultrasound. American Journal of Cardiology, 2011, 107, 1725-1729.	0.7	69
260	Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction. International Journal of Epidemiology, 2012, 41, 106-115.	0.9	69
261	Restenosis after PCI. Part 2: prevention and therapy. Nature Reviews Cardiology, 2012, 9, 79-90.	6.1	69
262	Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium. PLoS ONE, 2016, 11, e0144997.	1.1	69
263	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation, 2018, 138, 2499-2512.	1.6	69
264	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and AlcoholÂUse. Biological Psychiatry, 2019, 85, 946-955.	0.7	69
265	Activation of Nuclear Receptor Nur77 by 6-Mercaptopurine Protects Against Neointima Formation. Circulation, 2007, 115, 493-500.	1.6	68
266	Diabetes: Prognostic Value of CT Coronary Angiographyâ€"Comparison with a Nondiabetic Population. Radiology, 2010, 256, 83-92.	3.6	68
267	A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. European Heart Journal, 2012, 33, 165-175.	1.0	68
268	Cardiac multidetector-row computed tomography in patients with unstable angina. American Journal of Cardiology, 2005, 95, 457-461.	0.7	67
269	Genetic variation in the interleukin-1Â-converting enzyme associates with cognitive function. The PROSPER study. Brain, 2008, 131, 1069-1077.	3.7	67
270	Physiciansâ€™ attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Current Medical Research and Opinion, 2009, 25, 1171-1178.	0.9	67

#	Article	IF	Citations
271	Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4270-4282.	1.8	67
272	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. JAMA Cardiology, 2019, 4, 613.	3.0	66
273	Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions. Circulation, 2005, 112, 2417-2425.	1.6	65
274	KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 455-461.	3.1	65
275	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European Heart Journal, 2015, 36, 39-50.	1.0	65
276	Sex differences in body fat distribution are related to sex differences in serum leptin and adiponectin. Peptides, 2018, 107, 25-31.	1.2	65
277	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nature Reviews Cardiology, 2019, 16, 325-343.	6.1	65
278	Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(-caprolactone) stent cuff. Biomaterials, 2005, 26, 5386-5394.	5.7	64
279	Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Human Molecular Genetics, 2012, 21, 5329-5343.	1.4	64
280	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. JAMA Cardiology, 2019, 4, 144.	3.0	64
281	Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nature Communications, 2020, 11, 39.	5.8	64
282	Noninvasive Assessment of Plaque Characteristics With Multislice Computed Tomography Coronary Angiography in Symptomatic Diabetic Patients. Diabetes Care, 2007, 30, 1113-1119.	4.3	63
283	Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE, 2012, 7, e52438.	1.1	63
284	Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects. Circulation, 2016, 134, 212-221.	1.6	63
285	PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke. Circulation: Cardiovascular Genetics, 2017, 10, e001632.	5.1	63
286	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
287	Prevalence of Carriers of Intermediate and Pathological Polyglutamine Diseaseâ€“Associated Alleles Among Large Population-Based Cohorts. JAMA Neurology, 2019, 76, 650.	4.5	63
288	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	3.0	63

#	Article	IF	Citations
289	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	1.0	63
290	Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. American Heart Journal, 1998, 135, 571-576.	1.2	62
291	Evaluation of Patients with Previous Coronary Stent Implantation with 64-Section CT. Radiology, 2007, 245, 416-423.	3.6	62
292	Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion, 2008, 24, 2477-2487.	0.9	62
293	Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart, 2007, 93, 922-927.	1.2	61
294	Prevalence of Coronary Artery Disease Assessed by Multislice Computed Tomography Coronary Angiography in Patients With Paroxysmal or Persistent Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2009, 2, 100-106.	1.3	61
295	Usefulness of Peak Troponin-T to Predict Infarct Size and Long-Term Outcome in Patients With First Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 103, 779-784.	0.7	61
296	Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia, 2008, 51, 1581-1593.	2.9	60
297	Genetic Predictors of Fibrin D-Dimer Levels in Healthy Adults. Circulation, 2011, 123, 1864-1872.	1.6	60
298	Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS Trial). American Journal of Cardiology, 2000, 86, 742-746.	0.7	59
299	CETP gene variation: relation to lipid parameters and cardiovascular risk. Current Opinion in Lipidology, 2004, 15, 393-398.	1.2	59
300	Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 2008, 200, 95-101.	0.4	59
301	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research, 2014, 55, 2370-2379.	2.0	59
302	Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction. Nature Communications, 2020, 11, 2542.	5.8	59
303	Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?. Biomedicines, 2021, 9, 57.	1.4	59
304	LDLâ€€/HDLâ€€ ratio in subjects with cardiovascular disease and a low HDLâ€€: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research and Opinion, 2005, 21, 1865-1874.	0.9	58
305	Prognostic value of coronary vessel dominance in relation to significant coronary artery disease determined with non-invasive computed tomography coronary angiography. European Heart Journal, 2012, 33, 1367-1377.	1.0	58
306	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal, 2016, 178, 135-144.	1.2	58

#	Article	IF	Citations
307	Survival Bias in Mendelian Randomization Studies. Epidemiology, 2019, 30, 813-816.	1.2	58
308	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	1.2	58
309	Modulation of Lipoprotein(a) Atherogenicity by High Density Lipoprotein Cholesterol Levels in Middle-Aged Men With Symptomatic Coronary Artery Disease and Normal to Moderately Elevated Serum Cholesterol fn1fn1This study was supported by Bristol-Myers Squibb Co., Princeton, New Jersey (REGRESS main study) and by Grant 94.032 from the Dutch Heart Foundation, Den Haag, The Netherlands [lipoprotein(a) substudy].. Journal of the American College of Cardiology, 1997, 30, 1491-1499.	1.2	57
310	Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. European Heart Journal, 2004, 25, 1163-1170.	1.0	57
311	CCL3 (MIP-1Î±) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. Journal of Molecular and Cellular Cardiology, 2008, 45, 446-452.	0.9	57
312	Adipocytokines and risk of stroke in older people: a nested caseâ€“control study. International Journal of Epidemiology, 2009, 38, 253-261.	0.9	57
313	Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. European Journal of Heart Failure, 2013, 15, 581-588.	2.9	57
314	Noninvasive Angiography and Assessment of Left Ventricular Function Using Multislice Computed Tomography in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 2905-2910.	4.3	56
315	Automated Quantification of Stenosis Severity on 64-Slice CT. JACC: Cardiovascular Imaging, 2010, 3, 699-709.	2.3	56
316	Influence of Gender on Ischemic Times and Outcomes After ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2013, 111, 312-318.	0.7	56
317	High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis, 2008, 200, 161-167.	0.4	55
318	Diagnostic performance of 320-slice multidetector computed tomography coronary angiography in patients after coronary artery bypass grafting. European Radiology, 2011, 21, 2285-2296.	2.3	55
319	Bramwell-Hill modeling for local aortic pulse wave velocity estimation: a validation study with velocity-encoded cardiovascular magnetic resonance and invasive pressure assessment. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 15.	1.6	55
320	Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 93-104.	3.3	54
321	Gender influence on the diagnostic accuracy of 64-slice multislice computed tomography coronary angiography for detection of obstructive coronary artery disease. Heart, 2008, 94, 48-52.	1.2	54
322	Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis. PLoS Medicine, 2009, 6, e1000016.	3.9	54
323	Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis. Circulation: Cardiovascular Genetics, 2016, 9, 511-520.	5.1	54
324	Secondary prevention with folic acid: results of the Goes extension study. Heart, 2005, 91, 1213-1214.	1.2	53

#	Article	IF	Citations
325	A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. Journal of Clinical Pharmacology, 2007, 47, 1555-1569.	1.0	53
326	Apolipoprotein E Genotype, Plasma Cholesterol, and Cancer: A Mendelian Randomization Study. American Journal of Epidemiology, 2009, 170, 1415-1421.	1.6	53
327	The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace, 2011, 13, 634-639.	0.7	53
328	Literature-Based Genetic Risk Scores for Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2012, 5, 202-209.	5.1	53
329	Lysine Acetyltransferase PCAF Is a Key Regulator of Arteriogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1902-1910.	1.1	53
330	Heavier smoking may lead to a relative increase in waist circumference: evidence for a causal relationship from a Mendelian randomisation meta-analysis. The CARTA consortium: TableÂ1. BMJ Open, 2015, 5, e008808.	0.8	53
331	Subclinical Thyroid Dysfunction and Depressive Symptoms among the Elderly: A Prospective Cohort Study. Neuroendocrinology, 2016, 103, 291-299.	1.2	53
332	Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris. Circulation, 2000, 102, 1629-1633.	1.6	52
333	Subclinical Thyroid Dysfunction and Cognitive Decline in Old Age. PLoS ONE, 2013, 8, e59199.	1.1	52
334	Resting heart rate, heart rate variability and functional decline in old age. Cmaj, 2015, 187, E442-E449.	0.9	52
335	10-Second heart rate variability and cognitive function in old age. Neurology, 2016, 86, 1120-1127.	1.5	52
336	Myocardial Infarction in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Medicine (United States), 2003, 82, 251-256.	0.4	51
337	The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care, 2005, 28, 1668-1674.	4.3	51
338	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal, 2020, 41, 2248-2258.	1.0	51
339	Association of Thyroid Dysfunction With Cognitive Function. JAMA Internal Medicine, 2021, 181, 1440.	2.6	51
340	Risk of Cardiovascular Disease in a Traditional African Population with a High Infectious Load: A Population-Based Study. PLoS ONE, 2012, 7, e46855.	1.1	51
341	Functional interaction between â^'629C/A, â^'971G/A and â^'1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Human Molecular Genetics, 2005, 14, 2607-2618.	1.4	50
342	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 152-167.	1.4	50

#	Article	IF	Citations
343	Metabolic Age Based on the BBMRI-NL ¹ H-NMR Metabolomics Repository as Biomarker of Age-related Disease. Circulation Genomic and Precision Medicine, 2020, 13, 541-547.	1.6	50
344	Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial â€“ a prospective pilot study. Current Medical Research and Opinion, 2008, 24, 2151-2157.	0.9	49
345	Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 188-194.	1.1	49
346	2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal, 2017, 25, 181-185.	0.3	49
347	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	1.2	49
348	Both Paraoxonase-1 Genotype and Activity Do Not Predict the Risk of Future Coronary Artery Disease; the EPIC-Norfolk Prospective Population Study. PLoS ONE, 2009, 4, e6809.	1.1	48
349	Multislice computed tomography coronary angiography for risk stratification in patients with an intermediate pretest likelihood. Heart, 2009, 95, 1607-1611.	1.2	48
350	Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 2010, 51, 1201-1207.	2.0	48
351	Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research, 2010, 51, 202-209.	2.0	48
352	Diagnostic performance of non-invasive multidetector computed tomography coronary angiography to detect coronary artery disease using different endpoints: detection of significant stenosis vs. detection of atherosclerosis. European Heart Journal, 2011, 32, 637-645.	1.0	48
353	Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€˜OMicsâ€™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	2.3	48
354	2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal, 2018, 26, 417-421.	0.3	48
355	Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. Journal of Lipid Research, 2020, 61, 365-375.	2.0	48
356	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 75, 2297-2308.	1.2	48
357	Surrogate markers for atherosclerotic disease. Current Opinion in Lipidology, 2005, 16, 434-441.	1.2	47
358	Comprehensive cardiac assessment with multislice computed tomography: evaluation of left ventricular function and perfusion in addition to coronary anatomy in patients with previous myocardial infarction. Heart, 2006, 92, 1779-1783.	1.2	47
359	Nuclear magnetic resonanceâ€based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. European Journal of Heart Failure, 2018, 20, 663-673.	2.9	47
360	The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. Frontiers in Cardiovascular Medicine, 2018, 5, 55.	1.1	47

#	Article	IF	Citations
361	Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6. Genome Biology, 2018, 19, 87.	3.8	47
362	Initial stress in biomechanical models of atherosclerotic plaques. Journal of Biomechanics, 2011, 44, 2376-2382.	0.9	46
363	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 229-243.	1.4	46
364	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46
365	Improved MR Flow Mapping in Coronary Artery Bypass Grafts during Adenosine-induced Stress. Radiology, 2001, 218, 540-547.	3.6	45
366	Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clinical Genetics, 2006, 69, 263-270.	1.0	45
367	Plaque type and composition as evaluated non-invasively by MSCT angiography and invasively by VH IVUS in relation to the degree of stenosis. Heart, 2009, 95, 1990-1996.	1.2	45
368	Three-Year Outcome of Sirolimus-Eluting Versus Bare-Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction (from the MISSION! Intervention Study). American Journal of Cardiology, 2010, 106, 4-12.	0.7	45
369	Stratification by Smoking Status Reveals an Association of CHRNA5-A3-B4 Genotype with Body Mass Index in Never Smokers. PLoS Genetics, 2014, 10, e1004799.	1.5	45
370	Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. Nature Communications, 2015, 6, 6065.	5.8	45
371	Genome-wide association studies identify genetic loci for low von Willebrand factor levels. European Journal of Human Genetics, 2016, 24, 1035-1040.	1.4	45
372	Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. American Journal of Human Genetics, 2017, 100, 51-63.	2.6	45
373	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	1.0	45
374	Functional Evaluation of Lipid-Lowering Therapy by Pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation, 1997, 96, 429-435.	1.6	45
375	Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice. Journal of Cardiovascular Pharmacology, 2003, 42, 63-70.	0.8	44
376	Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention. Diabetes Care, 2005, 28, 873-877.	4.3	44
377	Improved aortic pulse wave velocity assessment from multislice twoâ€directional inâ€plane velocityâ€encoded magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2010, 32, 1086-1094.	1.9	44
378	Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis, 2011, 214, 295-300.	0.4	44

#	Article	IF	Citations
379	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	1.7	44
380	CETP (Cholesteryl Ester Transfer Protein) Concentration. Circulation Genomic and Precision Medicine, 2018, 11, e002034.	1.6	44
381	Molecular genetics and gene expression in atherosclerosis. International Journal of Cardiology, 2001, 80, 161-172.	0.8	43
382	Anatomic Correlates of a Normal Perfusion Scan Using 64-Slice Computed Tomographic Coronary Angiography. American Journal of Cardiology, 2008, 101, 40-45.	0.7	43
383	Differences in Atherosclerotic Plaque Burden and Morphology Between Type 1 and 2 Diabetes as Assessed by Multislice Computed Tomography. Diabetes Care, 2009, 32, 1507-1512.	4.3	43
384	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1093-1101.	1.1	43
385	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and olderâ€"rationale and design of the POPular AGE study. American Heart Journal, 2015, 170, 981-985.e1.	1.2	43
386	Estimation of Multilocus Haplotype Effects Using Weighted Penalised Log-Likelihood: Analysis of Five Sequence Variations at the Cholesteryl Ester Transfer Protein Gene Locus. Annals of Human Genetics, 2003, 67, 175-184.	0.3	42
387	Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opinion on Pharmacotherapy, 2004, 5, 459-468.	0.9	42
388	Noninvasive Evaluation of the Coronary Arteries With Multislice Computed Tomography in Hypertensive Patients. Hypertension, 2005, 45, 227-232.	1.3	42
389	Dual PPARÎ±/Î³ Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2560-2566.	1.1	42
390	Usefulness of Hypertriglyceridemic Waist Phenotype in Type 2 Diabetes Mellitus to Predict the Presence of Coronary Artery Disease as Assessed by Computed Tomographic Coronary Angiography. American Journal of Cardiology, 2010, 106, 1747-1753.	0.7	42
391	LDL cholesterol still a problem in old age? A Mendelian randomization study. International Journal of Epidemiology, 2015, 44, 604-612.	0.9	42
392	Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels. Journal of Internal Medicine, 2019, 285, 59-74.	2.7	42
393	Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): aÂposition paper from the Dutch ACS working group. Netherlands Heart Journal, 2020, 28, 116-130.	0.3	42
394	MR Flow Mapping in Coronary Artery Bypass Grafts: A Validation Study with Doppler Flow Measurements. Radiology, 2002, 222, 127-135.	3.6	41
395	Evaluation of Contraindications and Efficacy of Oral Beta Blockade Before Computed Tomographic Coronary Angiography. American Journal of Cardiology, 2010, 105, 767-772.	0.7	41
396	Plaque Rupture Complications in Murine Atherosclerotic Vein Grafts Can Be Prevented by TIMP-1 Overexpression. PLoS ONE, 2012, 7, e47134.	1.1	41

#	Article	IF	Citations
397	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE, 2013, 8, e72642.	1.1	41
398	Individual contributions of visceral fat and total body fat to subclinical atherosclerosis: The NEO study. Atherosclerosis, 2015, 241, 547-554.	0.4	41
399	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 3-12.	0.4	41
400	The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. Clinical Genetics, 1998, 53, 27-33.	1.0	41
401	Genetic Variation in the Interleukin-10 Gene Promoter and Risk of Coronary and Cerebrovascular Events: The PROSPER Study. Annals of the New York Academy of Sciences, 2007, 1100, 189-198.	1.8	40
402	Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Molecular and Cellular Biochemistry, 2008, 308, 25-33.	1.4	40
403	The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Current Medical Research and Opinion, 2008, 24, 685-694.	0.9	40
404	Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. American Heart Journal, 2009, 158, 860-866.	1.2	40
405	Human ATPâ€“Binding Cassette G1 Controls Macrophage Lipoprotein Lipase Bioavailability and Promotes Foam Cell Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2223-2231.	1.1	40
406	Association of common genetic variants with brain microbleeds. Neurology, 2020, 95, e3331-e3343.	1.5	40
407	Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thrombosis and Haemostasis, 2003, 90, 92-100.	1.8	39
408	Multi-slice computed tomography coronary angiography for ruling out suspected coronary artery disease: what is the prevalence of a normal study in a general clinical population?. European Heart Journal, 2008, 29, 2006-2013.	1.0	39
409	Impact of Clinical Presentation and Pretest Likelihood on the Relation Between Calcium Score and Computed Tomographic Coronary Angiography. American Journal of Cardiology, 2010, 106, 1675-1679.	0.7	39
410	Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Research and Treatment, 2011, 2011, 1-6.	0.5	39
411	Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace, 2013, 15, 290-296.	0.7	39
412	The Relation Between Thyroid Function and Anemia: A Pooled Analysis of Individual Participant Data. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3658-3667.	1.8	39
413	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical Research in Cardiology, 2019, 108, 520-538.	1.5	39
414	Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease. JAMA Internal Medicine, 2020, 180, 533.	2.6	39

#	Article	IF	Citations
415	A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: Evidence for publication bias. American Heart Journal, 2002, 144, 760-768.	1.2	39
416	Dipyridamole thallium-201 scintigraphy for improved detection of left anterior descending coronary artery stenosis in patients with left bundle branch block. European Heart Journal, 1993, 14, 53-56.	1.0	38
417	A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. Current Controlled Trials in Cardiovascular Medicine, 2002, 3, 8.	1.5	38
418	Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?. Current Pharmaceutical Design, 2007, 13, 1039-1052.	0.9	38
419	The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis, 2007, 193, 335-342.	0.4	38
420	Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Current Medical Research and Opinion, 2007, 23, 2235-2240.	0.9	38
421	Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics, 2012, 13, 831-840.	0.6	38
422	Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients. BMC Nephrology, 2014, 15, 197.	0.8	38
423	MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216. Cardiovascular Drugs and Therapy, 2017, 31, 381-389.	1.3	38
424	HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?. Current Cardiology Reports, 2018, 20, 66.	1.3	38
425	Assessment of obstruction length and optimal viewing angle from biplane X-ray angiograms. International Journal of Cardiovascular Imaging, 2010, 26, 5-17.	0.7	37
426	Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 605-611.	1.1	37
427	Toll-Like Receptor 4 Is Involved in Human and Mouse Vein Graft Remodeling, and Local Gene Silencing Reduces Vein Graft Disease in Hypercholesterolemic APOE*3Leiden Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1033-1040.	1.1	37
428	Blocking Toll-Like Receptors 7 and 9 Reduces Postinterventional Remodeling via Reduced Macrophage Activation, Foam Cell Formation, and Migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e72-80.	1.1	37
429	Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis. Atherosclerosis, 2017, 261, 26-36.	0.4	37
430	Human monocyte-to-macrophage differentiation involves highly localized gain and loss of DNA methylation at transcription factor binding sites. Epigenetics and Chromatin, 2019, 12, 34.	1.8	37
431	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.4	37
432	Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy. European Heart Journal, 2001, 22, 2058-2074.	1.0	36

#	Article	IF	Citations
433	A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. Atherosclerosis, 2003, 168, 131-138.	0.4	36
434	Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes and Immunity, 2007, 8, 44-50.	2.2	36
435	A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. Journal of Medical Genetics, 2014, 51, 122-131.	1.5	36
436	Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). BMC Endocrine Disorders, 2017, 17, 6.	0.9	36
437	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. PLoS ONE, 2013, 8, e66467.	1.1	36
438	Hepatic low-density lipoprotein receptorâ€“related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood, 2004, 103, 3777-3782.	0.6	35
439	Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*. Critical Care Medicine, 2008, 36, 2576-2582.	0.4	35
440	The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. European Heart Journal, 2009, 30, 1559-1564.	1.0	35
441	Assessment of global left ventricular function and volumes with 320-row multidetector computed tomography: A comparison with 2D-echocardiography. Journal of Nuclear Cardiology, 2010, 17, 225-231.	1.4	35
442	Comparison of the Relation Between the Calcium Score and Plaque Characteristics in Patients With Acute Coronary Syndrome Versus Patients With Stable Coronary Artery Disease, Assessed by Computed Tomography Angiography and Virtual Histology Intravascular Ultrasound. American Journal of Cardiology, 2011, 108, 658-664.	0.7	35
443	Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Medical Genetics, 2011, 12, 131.	2.1	35
444	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2. Atherosclerosis, 2012, 224, 150-153.	0.4	35
445	Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes. Neurology: Genetics, 2018, 4, e293.	0.9	35
446	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	1.0	35
447	Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis, 2002, 164, 65-71.	0.4	34
448	Type 2 diabetes is associated with more advanced coronary atherosclerosis on multislice computed tomography and virtual histology intravascular ultrasound. Journal of Nuclear Cardiology, 2009, 16, 376-383.	1.4	34
449	The dual PPARÎ±/Î³ agonist tesaglitazar blocks progression of preâ€existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. British Journal of Pharmacology, 2009, 156, 1067-1075.	2.7	34
450	Assessment With Multi-Slice Computed Tomography and Gray-Scale and Virtual Histology Intravascular Ultrasound of Gender-Specific Differences in Extent and Composition of Coronary Atherosclerotic Plaques in Relation to Age. American Journal of Cardiology, 2010, 105, 480-486.	0.7	34

#	Article	IF	Citations
451	Meta-analysis of 49â€…549 individuals imputed with the 1000 Genomes Project reveals an exonic damaging variant inANGPTL4determining fasting TG levels. Journal of Medical Genetics, 2016, 53, 441-449.	1.5	34
452	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
453	Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. PLoS Genetics, 2016, 12, e1006034.	1.5	34
454	PXR agonism decreases plasma HDL levels in ApoEâŽ3-Leiden.CETP mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 191-197.	1.2	33
455	Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. International Journal of Cardiology, 2009, 131, 285-287.	0.8	33
456	Common Variants in Mendelian Kidney Disease Genes and Their Association with Renal Function. Journal of the American Society of Nephrology: JASN, 2013, 24, 2105-2117.	3.0	33
457	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 2021, 28, 33-43.	0.8	33
458	Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7Î±-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clinical Science, 2005, 108, 539-545.	1.8	32
459	Assessment of left ventricular volumes and ejection fraction with 16-slice multi-slice computed tomography; comparison with 2D-echocardiography. International Journal of Cardiology, 2007, 116, 201-205.	0.8	32
460	Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Current Medical Research and Opinion, 2011, 27, 141-150.	0.9	32
461	Subclinical Thyroid Dysfunction and Functional Capacity Among Elderly. Thyroid, 2014, 24, 208-214.	2.4	32
462	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	1.4	32
463	The epigenetic factor PCAF regulates vascular inflammation and is essential for intimal hyperplasia development. PLoS ONE, 2017, 12, e0185820.	1.1	32
464	Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. EuroIntervention, 2011, 7, 505-516.	1.4	32
465	Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenetics and Genomics, 2006, 16, 331-337.	0.7	31
466	Global and regional left ventricular function: a comparison between gated SPECT, 2D echocardiography and multi-slice computed tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1452-1460.	3.3	31
467	Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Human Mutation, 2008, 29, 375-380.	1.1	31
468	Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 982-988.	1.7	31

#	Article	IF	Citations
469	Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. Scientific Reports, 2018, 8, 6753.	1.6	31
470	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. Nature Communications, 2018, 9, 3945.	5.8	31
471	Low thyroid function is not associated with an accelerated deterioration in renal function. Nephrology Dialysis Transplantation, 2019, 34, 650-659.	0.4	31
472	Catheter sizes for quantitative coronary arteriography. Catheterization and Cardiovascular Diagnosis, 1994, 33, 153-155.	0.7	30
473	Impact of coronary calcium score on diagnostic accuracy of multislice computed tomography coronary angiography for detection of coronary artery disease. Journal of Nuclear Cardiology, 2007, 14, 36-43.	1.4	30
474	Genetic variation in galectin-3 gene associates with cognitive function at old age. Neurobiology of Aging, 2012, 33, 2232.e1-2232.e9.	1.5	30
475	Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: The NEO study. Atherosclerosis, 2013, 229, 423-429.	0.4	30
476	Stratified Patient-Centered Care in Type 2 Diabetes. Diabetes Care, 2013, 36, 3054-3061.	4.3	30
477	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 2014, 57, 2513-2520.	2.9	30
478	Serum Cardiac Troponin-I is Superior to Troponin-T as a Marker for Left Ventricular Dysfunction in Clinically Stable Patients with End-Stage Renal Disease. PLoS ONE, 2015, 10, e0134245.	1.1	30
479	Prevalence of left ventricular systolic dysfunction in preâ€dialysis and dialysis patients with preserved left ventricular ejection fraction. European Journal of Heart Failure, 2018, 20, 560-568.	2.9	30
480	Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. European Journal of Human Genetics, 2019, 27, 422-431.	1.4	30
481	Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. Neurology, 2019, 92, .	1.5	30
482	Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults. Journal of Infectious Diseases, 2021, 223, 238-246.	1.9	30
483	Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy. PLoS ONE, 2012, 7, e38240.	1.1	30
484	Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention, 2012, 7, 1021-1029.	1.4	30
485	Elevated fibrinogen Î³â€² ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood, 2009, 114, 4603-4604.	0.6	29
486	Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 2012, 220, 413-417.	0.4	29

#	Article	IF	Citations
487	The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity. Thrombosis Research, 2012, 130, 935-941.	0.8	29
488	The role of insulin resistance in the association between body fat and autonomic function. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 93-99.	1.1	29
489	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	1.4	29
490	Genome-wide association meta-analysis of 30,000 samples identifies seven novel loci for quantitative ECG traits. European Journal of Human Genetics, 2019, 27, 952-962.	1.4	29
491	Detection of malignant right coronary artery anomaly by multi-slice CT coronary angiography. European Radiology, 2002, 12, S177-S180.	2.3	28
492	Apoliprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiologica, 2006, 61, 327-331.	0.3	28
493	Performance and efficacy of 320-row computed tomography coronary angiography in patients presenting with acute chest pain: results from a clinical registry. International Journal of Cardiovascular Imaging, 2012, 28, 865-876.	0.7	28
494	Body fat, especially visceral fat, is associated with electrocardiographic measures of sympathetic activation. Obesity, 2014, 22, 1553-1559.	1.5	28
495	Drugâ€“gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics Journal, 2014, 14, 6-13.	0.9	28
496	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
497	Pseudoaneurysm of a saphenous vein coronary artery bypass graft with a fistula draining into the right atrium. American Heart Journal, 1992, 124, 1397-1399.	1.2	27
498	An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clinical Science, 2004, 107, 255-261.	1.8	27
499	Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. Journal of Hypertension, 2007, 25, 2454-2462.	0.3	27
500	Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochemical and Biophysical Research Communications, 2008, 377, 1294-1298.	1.0	27
501	PPARÂ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients. Diabetes Care, 2009, 32, 839-844.	4.3	27
502	p27 ^{kip1} â€“838C>A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27 ^{kip1} Promoter Activity. Circulation, 2009, 120, 669-676.	1.6	27
503	Usefulness of Carotid Intima-Media Thickness in Patients With Diabetes Mellitus as a Predictor of Coronary Artery Disease. American Journal of Cardiology, 2009, 104, 1041-1046.	0.7	27
504	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. Journal of Hypertension, 2012, 30, 107-116.	0.3	27

#	Article	IF	Citations
505	KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis, 2012, 220, 456-462.	0.4	27
506	Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease. Biomarkers in Medicine, 2012, 6, 35-52.	0.6	27
507	Acute myocardial infarction system of care in the third world. Netherlands Heart Journal, 2012, 20, 254-259.	0.3	27
508	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 2882-2888.	0.8	27
509	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. Journal of Lipid Research, 2015, 56, 2085-2093.	2.0	27
510	White Matter Lesion Progression. Stroke, 2015, 46, 3048-3057.	1.0	27
511	Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. European Journal of Clinical Pharmacology, 2016, 72, 431-437.	0.8	27
512	ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals. Circulation Genomic and Precision Medicine, 2018, 11, e001758.	1.6	27
513	Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals. Journal of the American College of Cardiology, 2019, 73, 3118-3131.	1.2	27
514	Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. Journal of Molecular and Cellular Cardiology, 2003, 35, 109-118.	0.9	26
515	ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients. Current Medical Research and Opinion, 2008, 24, 359-364.	0.9	26
516	Prevalence of coronary artery disease across the Framingham risk categories: coronary artery calcium scoring and MSCT coronary angiography. Journal of Nuclear Cardiology, 2009, 16, 368-375.	1.4	26
517	Combined non-invasive anatomical and functional assessment with MSCT and MRI for the detection of significant coronary artery disease in patients with an intermediate pre-test likelihood. Heart, 2010, 96, 425-431.	1.2	26
518	Clinical Application of CT Coronary Angiography: State of the Art. Heart Lung and Circulation, 2010, 19, 107-116.	0.2	26
519	Late acquired stent malapposition: why, when and how to handle?. Heart, 2012, 98, 1529-1536.	1.2	26
520	Non-invasive assessment of microcirculation by sidestream dark field imaging as a marker of coronary artery disease in diabetes. Diabetes and Vascular Disease Research, 2013, 10, 123-134.	0.9	26
521	Erythrocyte-Bound Apolipoprotein B in Relation to Atherosclerosis, Serum Lipids and ABO Blood Group. PLoS ONE, 2013, 8, e75573.	1.1	26
522	Comparison by Computed Tomographic Angiographyâ€"The Presence and Extent of Coronary Arterial Atherosclerosis in South Asians Versus Caucasians With Diabetes Mellitus. American Journal of Cardiology, 2014, 113, 1782-1787.	0.7	26

#	Article	IF	Citations
523	Executive function, but not memory, associates with incident coronary heart disease and stroke. Neurology, 2015, 85, 783-789.	1.5	26
524	Accuracy and reproducibility of fast fractional flow reserve computation from invasive coronary angiography. International Journal of Cardiovascular Imaging, 2017, 33, 1305-1312.	0.7	26
525	Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes. Nutrition and Diabetes, 2018, 8, 6.	1.5	26
526	The Routine Electrocardiogram for Cardiovascular Risk Stratification in Old Age: The Leiden 85-Plus Study. Journal of the American Geriatrics Society, 2007, 55, 872-877.	1.3	25
527	Prognostic Implications of Left Ventricular Global Longitudinal Strain in Predialysis and Dialysis Patients. American Journal of Cardiology, 2017, 120, 500-504.	0.7	25
528	Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovascular Research, 2019, 115, 1519-1532.	1.8	25
529	Effects of fatty acids on T cell function: role in atherosclerosis. Nature Reviews Cardiology, 2021, 18, 824-837.	6.1	25
530	CT Coronary Angiography Is Feasible for the Assessment of Coronary Artery Disease in Chronic Dialysis Patients, Despite High Average Calcium Scores. PLoS ONE, 2013, 8, e67936.	1.1	25
531	Increased risk for ischaemic events is related to combined RAS polymorphism. British Heart Journal, 2001, 85, 458-462.	2.2	24
532	High Innate Production Capacity of Proinflammatory Cytokines Increases Risk for Death from Cancer: Results of the PROSPER Study. Clinical Cancer Research, 2009, 15, 7744-7748.	3.2	24
533	Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 2010, 210, 28-34.	0.4	24
534	Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. International Journal of Cardiovascular Imaging, 2011, 27, 777-785.	0.7	24
535	Left Ventricular Diastolic Dysfunction in Dialysis Patients Assessed by Novel Speckle Tracking Strain Rate Analysis: Prevalence and Determinants. International Journal of Nephrology, 2012, 2012, 1-7.	0.7	24
536	Homocysteine Levels and Treatment Effect in the Prospective Study of Pravastatin in the Elderly at Risk. Journal of the American Geriatrics Society, 2014, 62, 213-221.	1.3	24
537	Metabolomics Profiling of Visceral Adipose Tissue: Results From MESA and the NEO Study. Journal of the American Heart Association, 2019, 8, e010810.	1.6	24
538	Association of Circulating Metabolites in Plasma or Serum and Risk of Stroke. Neurology, 2021, 96, .	1.5	24
539	Impact of computed tomography myocardial perfusion following computed tomography coronary angiography on downstream referral for invasive coronary angiography, revascularization and, outcome at 12 months. European Heart Journal Cardiovascular Imaging, 2017, 18, 969-977.	0.5	24
540	Diagnosis and management of anomalous origin of the right coronary artery from the left coronary sinus. International Journal of Cardiovascular Imaging, 1999, 15, 253-258.	0.2	23

#	Article	IF	Citations
541	Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovascular Research, 2005, 68, 415-424.	1.8	23
542	Usefulness of Echocardiographic Assessment of Cardiac and Ascending Aorta Calcific Deposits to Predict Coronary Artery Calcium and Presence and Severity of Obstructive Coronary Artery Disease. American Journal of Cardiology, 2009, 103, 1045-1050.	0.7	23
543	Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. Expert Opinion on Therapeutic Targets, 2010, 14, 243-251.	1.5	23
544	Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion, 2010, 26, 2301-2313.	0.9	23
545	Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. Journal of Cellular and Molecular Medicine, 2012, 16, 1866-1877.	1.6	23
546	Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clinical Research in Cardiology, 2013, 102, 847-856.	1.5	23
547	PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. Journal of Lipid Research, 2013, 54, 561-566.	2.0	23
548	Scarcity of atrial fibrillation in a traditional African population: a community-based study. BMC Cardiovascular Disorders, 2014, 14, 87.	0.7	23
549	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	1.5	23
550	Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study. BMJ Open, 2018, 8, e019003.	0.8	23
551	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atherosclerosis Supplements, 2020, 42, e49-e58.	1.2	23
552	TLR Accessory Molecule RP105 (CD180) Is Involved in Post-Interventional Vascular Remodeling and Soluble RP105 Modulates Neointima Formation. PLoS ONE, 2013, 8, e67923.	1.1	23
553	Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal, 2022, 43, 1554-1565.	1.0	23
554	Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction. American Journal of Cardiology, 2000, 86, 774-776.	0.7	22
555	Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Atherosclerosis, 2012, 221, 333-340.	0.4	22
556	Age- and gender-specific differences in the prognostic value of CT coronary angiography. Heart, 2012, 98, 232-237.	1.2	22
557	An Unexpected Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation With Alterations on B-Cell Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2810-2817.	1.1	22
558	Total cerebral blood flow and mortality in old age. Neurology, 2013, 81, 1922-1929.	1.5	22

#	Article	IF	Citations
559	Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles. European Journal of Preventive Cardiology, 2017, 24, 492-504.	0.8	22
560	Complement receptor 1 gene polymorphisms are associated with cardiovascular risk. Atherosclerosis, 2017, 257, 16-21.	0.4	22
561	Left Ventricular Mechanical Dispersion and Global Longitudinal Strain and Ventricular Arrhythmias in Predialysis and Dialysis Patients. Journal of the American Society of Echocardiography, 2018, 31, 777-783.	1.2	22
562	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
563	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Medicine, 2021, 19, 139.	2.3	22
564	Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy. Pharmacological Research, 1994, 29, 261-272.	3.1	21
565	Coronary Magnetic Resonance Angiography: Technical Developments and Clinical Applications. Journal of Cardiovascular Magnetic Resonance, 2003, 5, 365-386.	1.6	21
566	Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. American Heart Journal, 2004, 147, 181-186.	1.2	21
567	Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. European Journal of Human Genetics, 2005, 13, 445-451.	1.4	21
568	Effect of Intracoronary Aqueous Oxygen on Left Ventricular Remodeling After Anterior Wall ST-Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2005, 96, 22-24.	0.7	21
569	Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice. Journal of Cardiovascular Pharmacology, 2006, 47, 89-95.	0.8	21
570	Do risk factors influence the diagnostic accuracy of noninvasive coronary angiography with multislice computed tomography?. Journal of Nuclear Cardiology, 2006, 13, 635-641.	1.4	21
571	Pravastatin Decreases Wall Shear Stress and Blood Velocity in the Internal Carotid Artery Without Affecting Flow Volume. Stroke, 2007, 38, 1374-1376.	1.0	21
572	Invasive Versus Noninvasive Evaluation of Coronary Artery Disease. JACC: Cardiovascular Imaging, 2008, 1, 190-199.	2.3	21
573	Gender-dependent effects of high-fat lard diet on cardiac function in C57Bl/6J mice. Applied Physiology, Nutrition and Metabolism, 2012, 37, 214-224.	0.9	21
574	Association between angiographic culprit lesion and out-of-hospital cardiac arrest in ST-elevation myocardial infarction patients. Resuscitation, 2013, 84, 1530-1535.	1.3	21
575	Polygenic Overlap Between Kidney Function and Large Artery Atherosclerotic Stroke. Stroke, 2014, 45, 3508-3513.	1.0	21
576	Chronic Kidney Disease and Implantable Cardioverter Defibrillator Related Complications: 16 Years of Experience. Journal of Cardiovascular Electrophysiology, 2014, 25, 998-1004.	0.8	21

#	Article	IF	Citations
577	Pre-infarction angina predicts thrombus burden in patients admitted for ST-segment elevation myocardial infarction. EuroIntervention, 2012, 7, 1396-1405.	1.4	21
578	Subclinical left ventricular dysfunction and coronary atherosclerosis in asymptomatic patients with type 2 diabetes. European Journal of Echocardiography, 2011, 12, 148-155.	2.3	20
579	High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk. European Journal of Preventive Cardiology, 2016, 23, 1383-1392.	0.8	20
580	Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice. Toxicological Sciences, 2019, 168, 519-534.	1.4	20
581	Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study. PLoS ONE, 2012, 7, e42401.	1.1	20
582	Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists. Cardiovascular Research, 2007, 73, 217-226.	1.8	19
583	Diagnostic Accuracy of 64-Slice Multislice Computed Tomographic Coronary Angiography in Patients With an Intermediate Pretest Likelihood for Coronary Artery Disease. American Journal of Cardiology, 2010, 105, 302-305.	0.7	19
584	A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovascular Research, 2010, 88, 367-375.	1.8	19
585	Relationship between left ventricular diastolic function and arterial stiffness in asymptomatic patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2013, 29, 609-616.	0.7	19
586	Heart rate variability, but not heart rate, is associated with handgrip strength and mortality in older Africans at very low cardiovascular risk: A population-based study. International Journal of Cardiology, 2015, 187, 559-561.	0.8	19
587	Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. Journal of Thrombosis and Haemostasis, 2018, 16, 519-528.	1.9	19
588	Common and Rare Coding Genetic Variation Underlying the Electrocardiographic PR Interval. Circulation Genomic and Precision Medicine, 2018, 11, e002037.	1.6	19
589	An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms. Scientific Reports, 2020, 10, 19111.	1.6	19
590	Optical Coherence Tomography: Current Applications for the Assessment of Coronary Artery Disease and Guidance of Percutaneous Coronary Interventions. Cardiology and Therapy, 2020, 9, 307-321.	1.1	19
591	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	4.3	19
592	â€“455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thrombosis and Haemostasis, 2005, 93, 564-569.	1.8	18
593	Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart, 2011, 97, 143-150.	1.2	18
594	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. Journal of Internal Medicine, 2012, 271, 521-536.	2.7	18

#	Article	IF	Citations
595	Increased cytokine response after toll-like receptor stimulation in patients with stable coronary artery disease. Atherosclerosis, 2013, 231, 346-351.	0.4	18
596	Nâ€terminal proâ€“brain natriuretic peptide and cognitive decline in older adults at high cardiovascular risk. Annals of Neurology, 2014, 76, 213-222.	2.8	18
597	Prognostic value of coronary computed tomography angiography in diabetic patients without chest pain syndrome. Journal of Nuclear Cardiology, 2016, 23, 24-36.	1.4	18
598	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	1.4	18
599	Relationship Between Coronary Contrast-Flow Quantitative Flow Ratio and Myocardial Ischemia Assessed by SPECT MPI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1888-1896.	3.3	18
600	Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. Pharmacogenomics Journal, 2020, 20, 462-470.	0.9	18
601	Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials. Frontiers in Endocrinology, 2021, 12, 674841.	1.5	18
602	Vein Graft Function Improvement after Percutaneous Intervention: Evaluation with MR Flow Mapping. Radiology, 2003, 228, 834-841.	3.6	17
603	Hemodynamic evaluation of saphenous vein coronary artery bypass grafts: Relative merits of Doppler flow velocity and SPECT perfusion imaging. Journal of Nuclear Cardiology, 2005, 12, 545-552.	1.4	17
604	Comparison of Non-Invasive Multi-Slice Computed Tomography Coronary Angiography Versus Invasive Coronary Angiography and Fractional Flow Reserve for the Evaluation of Men With Known Coronary Artery Diseaseâ€âConflicts of interest: Dr. Schalij received grants from Biotronik, Nijmegen, The Netherlands; Medtronic, Inc., Tolochenaz, Switzerland; and Boston Scientific Corporation, Maastricht, The Netherlands. Dr. Pundziute receives grants from Toshiba Medical Systems Europe, Zoetermeer, The Netherlands. Dr. Bax r. American Journal of Cardiology, 2009, 104, 653-656.	0.7	17
605	The value of multi-slice-computed tomography coronary angiography for risk stratification. Journal of Nuclear Cardiology, 2009, 16, 970-980.	1.4	17
606	Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia, 2009, 52, 235-239.	2.9	17
607	Standardised pre-hospital care of acute myocardial infarction patients: MISSION! guidelines applied in practice. Netherlands Heart Journal, 2010, 18, 408-415.	0.3	17
608	Predictive Value of Multislice Computed Tomography Variables of Atherosclerosis for Ischemia on Stress-Rest Single-Photon Emission Computed Tomography. Circulation: Cardiovascular Imaging, 2010, 3, 718-726.	1.3	17
609	Increased Carotid Intima-Media Thickness as a Predictor of the Presence and Extent of Abnormal Myocardial Perfusion in Type 2 Diabetes. Diabetes Care, 2010, 33, 372-374.	4.3	17
610	TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies. Arthritis Research and Therapy, 2010, 12, R38.	1.6	17
611	Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Current Medical Research and Opinion, 2010, 26, 2589-2597.	0.9	17
612	Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. Liver Transplantation, 2011, 17, 261-269.	1.3	17

#	Article	IF	Citations
613	Non-Homologous End-Joining Pathway Associated with Occurrence of Myocardial Infarction: Gene Set Analysis of Genome-Wide Association Study Data. PLoS ONE, 2013, 8, e56262.	1.1	17
614	Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study. European Journal of Epidemiology, 2014, 29, 841-850.	2.5	17
615	Visit-to-visit blood pressure variability and future functional decline in old age. Journal of Hypertension, 2016, 34, 1544-1550.	0.3	17
616	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis, 2017, 257, 186-194.	0.4	17
617	Left Ventricular Hypertrophy and Cognitive Decline in Old Age. Journal of Alzheimer's Disease, 2017, 58, 275-283.	1.2	17
618	Long-Term Prognosis of Patients With Intramural Course of Coronary Arteries Assessed With CT Angiography. JACC: Cardiovascular Imaging, 2017, 10, 1451-1458.	2.3	17
619	Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
620	Visit-to-visit lipid variability: Clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics. Journal of Clinical Lipidology, 2018, 12, 266-276.e3.	0.6	17
621	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	0.9	17
622	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. American Journal of Hypertension, 2019, 32, 1146-1153.	1.0	17
623	The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 728-735.	1.1	17
624	Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS ONE, 2019, 14, e0216222.	1.1	17
625	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
626	Referral of patients for fractional flow reserve using quantitative flow ratio. European Heart Journal Cardiovascular Imaging, 2019, 20, 1231-1238.	0.5	17
627	Role of Calcified Spots Detected by Intravascular Ultrasound in Patients With ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2006, 98, 309-313.	0.7	16
628	Endothelial Dysfunction in Diabetic Patients with Abnormal Myocardial Perfusion in the Absence of Epicardial Obstructive Coronary Artery Disease. Journal of Nuclear Medicine, 2009, 50, 1980-1986.	2.8	16
629	Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics, 2011, 11, 8.	1.1	16
630	Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography. International Journal of Cardiovascular Imaging, 2013, 29, 221-228.	0.7	16

#	Article	IF	Citations
631	Differential Complement Activation Pathways Promote C3b Deposition on Native and Acetylated LDL thereby Inducing Lipoprotein Binding to the Complement Receptor 1. Journal of Biological Chemistry, 2014, 289, 35421-35430.	1.6	16
632	ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment. Atherosclerosis, 2014, 235, 176-181.	0.4	16
633	Prevalence by Computed Tomographic Angiography of Coronary Plaques in South Asian and White Patients With Type 2 Diabetes Mellitus at Low and High Risk Using Four Cardiovascular Risk Scores (UKPDS, FRS, ASCVD, and JBS3). American Journal of Cardiology, 2017, 119, 705-711.	0.7	16
634	Monocyte gene expression in childhood obesity is associated with obesity and complexity of atherosclerosis in adults. Scientific Reports, 2017, 7, 16826.	1.6	16
635	The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis. International Journal of Cardiology, 2018, 260, 184-190.	0.8	16
636	Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention, 2009, 4, 662-668.	1.4	16
637	Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovascular Drugs and Therapy, 1998, 12, 111-118.	1.3	15
638	Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium. PLoS ONE, 2015, 10, e0140496.	1.1	15
639	Blood Pressure Lowering Medication, Visit-to-Visit Blood Pressure Variability, and Cognitive Function in Old Age. American Journal of Hypertension, 2016, 29, 311-318.	1.0	15
640	Gene-gene Interaction Analyses for Atrial Fibrillation. Scientific Reports, 2016, 6, 35371.	1.6	15
641	Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus. American Journal of Cardiology, 2016, 117, 887-893.	0.7	15
642	Association between Hepatic Triglyceride Content and Left Ventricular Diastolic Function in a Population-based Cohort: The Netherlands Epidemiology of Obesity Study. Radiology, 2016, 279, 443-450.	3.6	15
643	Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Scientific Reports, 2017, 7, 11303.	1.6	15
644	Normal and reference values for cardiovascular magnetic resonance-based pulse wave velocity in the middle-aged general population. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 46.	1.6	15
645	Temporal Trends of System of Care for STEMI: Insights from the Jakarta Cardiovascular Care Unit Network System. PLoS ONE, 2014, 9, e86665.	1.1	15
646	Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2021, 50, 318-325.	0.7	15
647	Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis. Thrombosis and Haemostasis, 2004, 91, 986-990.	1.8	14
648	Genetic predictive factors in restenosis. Pathologie Et Biologie, 2004, 52, 186-195.	2.2	14

#	Article	IF	Citations
649	No Effect of Statin Therapy on Silent Myocardial Ischemia in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care, 2005, 28, 1675-1679.	4.3	14
650	Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics, 2006, 16, 747-754.	0.7	14
651	The current status of multislice computed tomography in the diagnosis and prognosis of coronary artery disease. Journal of Nuclear Cardiology, 2007, 14, 604-612.	1.4	14
652	Prognostic Value of Renal Dysfunction for the Prediction of Outcome Versus Results of Computed Tomographic Coronary Angiography. American Journal of Cardiology, 2011, 108, 968-972.	0.7	14
653	Different value of coronary calcium score to predict obstructive coronary artery disease in patients with and without moderate chronic kidney disease. Netherlands Heart Journal, 2013, 21, 347-353.	0.3	14
654	The maximum necrotic core area is most often located proximally to the site of most severe narrowing: a virtual histology intravascular ultrasound study. Heart and Vessels, 2013, 28, 166-172.	0.5	14
655	Candidate Gene Analysis of Arteriovenous Fistula Failure in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1358-1366.	2.2	14
656	Very-Low-Calorie Diet Increases Myocardial Triglyceride Content and Decreases Diastolic Left Ventricular Function in Type 2 Diabetes With Cardiac Complications. Diabetes Care, 2014, 37, e1-e2.	4.3	14
657	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 254-262.	0.4	14
658	Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. Current Opinion in Lipidology, 2018, 29, 51-52.	1.2	14
659	Assessment of novel cardiovascular biomarkers in women with a history of recurrent miscarriage. Pregnancy Hypertension, 2018, 11, 129-135.	0.6	14
660	The association between blood pressure variability (BPV) with dementia and cognitive function: a systematic review and meta-analysis protocol. Systematic Reviews, 2018, 7, 163.	2.5	14
661	IRF3 and IRF7 mediate neovascularization via inflammatory cytokines. Journal of Cellular and Molecular Medicine, 2019, 23, 3888-3896.	1.6	14
662	Association of alcohol consumption with allergic disease and asthma: a multiâ€centre Mendelian randomization analysis. Addiction, 2019, 114, 216-225.	1.7	14
663	The Role of Immunomodulation in Vein Graft Remodeling and Failure. Journal of Cardiovascular Translational Research, 2021, 14, 100-109.	1.1	14
664	Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses. BMC Medicine, 2021, 19, 69.	2.3	14
665	Analysis of lipoprotein lipase haplotypes reveals associations not apparent from analysis of the constituent loci. Annals of Human Genetics, 1999, 63, 499-510.	0.3	13
666	Simultaneous estimation of gene-gene and gene-environment interactions for numerous loci using double penalized logâ€likelihood. Genetic Epidemiology, 2006, 30, 645-651.	0.6	13

#	Article	IF	Citations
667	Noninvasive Assessment of Left Ventricular Function Prior to and 6 Months After Renal Transplantation. Transplantation Proceedings, 2007, 39, 3159-3162.	0.3	13
668	Mannose binding lectin deficiency and triglyceride-rich lipoprotein metabolism in normolipidemic subjects. Atherosclerosis, 2009, 206, 444-450.	0.4	13
669	Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Netherlands Heart Journal, 2011, 19, 61-67.	0.3	13
670	A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. Human Molecular Genetics, 2011, 20, 4748-4757.	1.4	13
671	Influence of smoking on the prognostic value of cardiovascular computed tomography coronary angiography. European Heart Journal, 2011, 32, 365-370.	1.0	13
672	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 232-244.	1.4	13
673	HDL functionality in South Asians as compared to white Caucasians. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 697-705.	1.1	13
674	Low levels of apolipoprotein-CII in normotriglyceridemic patients with very premature coronary artery disease: Observations from the MISSION! Intervention study. Journal of Clinical Lipidology, 2017, 11, 1407-1414.	0.6	13
675	Association of metabolic syndrome and electrocardiographic markers of subclinical cardiovascular disease. Diabetology and Metabolic Syndrome, 2017, 9, 40.	1.2	13
676	Comparison of Diagnostic Performance of Quantitative Flow Ratio in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2019, 123, 1722-1728.	0.7	13
677	Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 94-103.	1.4	13
678	The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. Cells, 2021, 10, 737.	1.8	13
679	Lipoprotein Lipase Gene Polymorphisms and the Risk of Target Vessel Revascularization After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2005, 46, 1093-1100.	1.2	12
680	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439.	1.3	12
681	Biological Correlates of Blood Pressure Variability in Elderly at High Risk of Cardiovascular Disease. American Journal of Hypertension, 2015, 28, 469-479.	1.0	12
682	Increasing HDL-C levels with medication. Current Opinion in Lipidology, 2017, 28, 361-366.	1.2	12
683	Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics Journal, 2018, 18, 127-135.	0.9	12
684	Prevalence and Prognostic Implications of Mitral and Aortic Valve Calcium in Patients With Chronic Kidney Disease. American Journal of Cardiology, 2018, 122, 1732-1737.	0.7	12

#	Article	IF	Citations
685	Increased cardiovascular disease risk in women with a history of recurrent miscarriage. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 1192-1199.	1.3	12
686	Spatial QRS-T Angle and Cognitive Decline in Older Subjects. Journal of Alzheimer's Disease, 2019, 67, 279-289.	1.2	12
687	Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. Journal of Internal Medicine, 2021, 290, 141-156.	2.7	12
688	Pathway Analysis Using Genome-Wide Association Study Data for Coronary Restenosis â€“ A Potential Role for the PARVB Gene. PLoS ONE, 2013, 8, e70676.	1.1	12
689	Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetesâ€”Prespecified Analyses of ODYSSEY OUTCOMES. Diabetes, 2018, 67, .	0.3	12
690	Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients. EuroIntervention, 2013, 8, 1199-1206.	1.4	12
691	Heart rate variability profiles in symptomatic coronary artery disease and preserved left ventricular function: Relation to ventricular tachycardia and transient myocardial ischemia. American Heart Journal, 1995, 130, 1020-1025.	1.2	11
692	Stenting of long coronary artery lesions: Initial angiographic results and 6-month clinical outcome of the micro stent II-XL. Catheterization and Cardiovascular Interventions, 1999, 48, 105-112.	0.7	11
693	Local Cre-Mediated Gene Recombination in Vascular Smooth Muscle Cells in Mice. Transgenic Research, 2006, 15, 31-36.	1.3	11
694	A genome wide association analysis in the GENDER study. Netherlands Heart Journal, 2009, 17, 262-264.	0.3	11
695	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. European Journal of Internal Medicine, 2010, 21, 293-296.	1.0	11
696	ABCA1 impacts athero-thrombotic risk and 10-year survival in a contemporary secondary prevention setting. Atherosclerosis, 2011, 218, 457-463.	0.4	11
697	Association of atherosclerosis in the descending thoracic aorta with coronary artery disease on multi detector row computed tomography coronary angiography in patients with suspected coronary artery disease. International Journal of Cardiovascular Imaging, 2013, 29, 1829-1837.	0.7	11
698	Journey Through Cholesteryl Ester Transfer Protein Inhibition. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 360-366.	0.9	11
699	Vitamin D3 mediated effects on postprandial leukocyte activation and arterial stiffness in men and women. European Journal of Clinical Nutrition, 2014, 68, 635-637.	1.3	11
700	Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. Pharmacogenomics, 2016, 17, 1621-1628.	0.6	11
701	Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. International Journal of Cardiology, 2017, 240, 20-24.	0.8	11
702	A protective role of <scp>IRF</scp>3 and <scp>IRF</scp>7 signalling downstream <scp>TLR</scp>s in the development of vein graft disease via type I interferons. Journal of Internal Medicine, 2017, 282, 522-536.	2.7	11

#	Article	IF	Citations
703	Myostatin Inhibits Vascular Smooth Muscle Cell Proliferation and Local 14q32 microRNA Expression, But Not Systemic Inflammation or Restenosis. International Journal of Molecular Sciences, 2020, 21, 3508.	1.8	11
704	Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. Angiogenesis, 2021, 24, 567-581.	3.7	11
705	Genetically Determined Serum Calcium Levels and Markers of Ventricular Repolarization: A Mendelian Randomization Study in the UK Biobank. Circulation Genomic and Precision Medicine, 2021, 14, e003231.	1.6	11
706	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	1.4	11
707	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	1.4	11
708	Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling. BMC Medicine, 2021, 19, 266.	2.3	11
709	Dietâ€Derived Antioxidants Do Not Decrease Risk of Ischemic Stroke: A Mendelian Randomization Study in 1ÂMillion People. Journal of the American Heart Association, 2021, 10, e022567.	1.6	11
710	Micro stent I, initial results, and six months follow-up by quantitative coronary angiography. Catheterization and Cardiovascular Diagnosis, 1998, 43, 19-27.	0.7	10
711	Matching treatment to the genetic basis of (lipid) disorder in patients with coronary artery disease. Heart, 1999, 82, 126-127.	1.2	10
712	Blood Flow in Coronary Artery Bypass Vein Grafts: Volume versus Velocity at Cardiovascular MR Imaging. Radiology, 2004, 232, 915-920.	3.6	10
713	Drug-eluting stents studies in mice: Do we need atherosclerosis to study restenosis?. Vascular Pharmacology, 2006, 44, 257-264.	1.0	10
714	Validation of a High-Resolution, Phase Contrast Cardiovascular Magnetic Resonance Sequence for Evaluation of Flow in Coronary Artery Bypass Grafts. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 557-563.	1.6	10
715	The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thrombosis and Haemostasis, 2007, 98, 1323-1328.	1.8	10
716	Epigenetic histone acetylation modifiers in vascular remodelling â€“ new targets for therapy in cardiovascular disease. Netherlands Heart Journal, 2008, 16, 30-32.	0.3	10
717	Coronary angiography enhancement for visualization. International Journal of Cardiovascular Imaging, 2009, 25, 657-667.	0.7	10
718	Incremental prognostic value of left ventricular function analysis over non-invasive coronary angiography with multidetector computed tomography. Journal of Nuclear Cardiology, 2010, 17, 1034-1040.	1.4	10
719	Relationship between vascular stiffness and stress myocardial perfusion imaging in asymptomatic patients with diabetes. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2050-2057.	3.3	10
720	Non-invasive assessment of atherosclerotic coronary lesion length using multidetector computed tomography angiography: comparison to quantitative coronary angiography. International Journal of Cardiovascular Imaging, 2012, 28, 2065-2071.	0.7	10

#	Article	IF	Citations
721	Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality. Netherlands Heart Journal, 2014, 22, 186-189.	0.3	10
722	The multifaceted interplay between lipids and epigenetics. Current Opinion in Lipidology, 2016, 27, 288-294.	1.2	10
723	Abdominal aortic calcification on a plain X-ray and the relation with significant coronary artery disease in asymptomatic chronic dialysis patients. BMC Nephrology, 2017, 18, 82.	0.8	10
724	Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. International Journal of Cardiology, 2017, 244, 298-302.	0.8	10
725	Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study. Journal of Clinical Lipidology, 2018, 12, 137-144.e1.	0.6	10
726	The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis. BMC Nephrology, 2020, 21, 81.	0.8	10
727	Association of cardiovascular structure and function with cerebrovascular changes and cognitive function in older patients with end-stage renal disease. Aging, 2020, 12, 1496-1511.	1.4	10
728	The â^'323Ins10 Polymorphism for Factor VII Is Not Associated with Coronary Atherosclerosis in Symptomatic Men. Thrombosis Research, 2000, 97, 275-280.	0.8	9
729	Continuous on-line measurement of absolute left ventricular volume by transcardiac conductance: Angiographic validation in sheep. Critical Care Medicine, 2002, 30, 1301-1305.	0.4	9
730	Tailored Therapy to Fit Individual Profiles: Genetics and Coronary Artery Disease. Annals of the New York Academy of Sciences, 2000, 902, 17-26.	1.8	9
731	Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Experimental Gerontology, 2008, 43, 801-805.	1.2	9
732	Statins: established indications and controversial subgroups. Heart, 2008, 94, 1656-1662.	1.2	9
733	Serum CETP concentration is not associated with measures of body fat: The NEO study. Atherosclerosis, 2016, 246, 267-273.	0.4	9
734	A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Journal of Medical Genetics, 2017, 54, 313-323.	1.5	9
735	Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. Pharmacogenomics Journal, 2018, 18, 215-226.	0.9	9
736	Genome-Wide Association Study on the Early-Phase Insulin Response to a Liquid Mixed Meal: Results From the NEO Study. Diabetes, 2019, 68, 2327-2336.	0.3	9
737	The first multicentre study on coronary anomalies in the Netherlands: MuSCAT. Netherlands Heart Journal, 2021, 29, 311-317.	0.3	9
738	2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation. Netherlands Heart Journal, 2021, 29, 557-565.	0.3	9

#	Article	IF	Citations
739	Nuclear medicine imaging methods of radiation-induced cardiotoxicity. Seminars in Nuclear Medicine, 2022, 52, 597-610.	2.5	9
740	Factor VII Polymorphisms and Myocardial Infarction: What Is Special in Italians?. Thrombosis and Haemostasis, 2001, 85, 746-747.	1.8	8
741	Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the respond study. American Journal of Hypertension, 2005, 18, A92-A93.	1.0	8
742	Automated determination of optimal angiographic viewing angles for coronary artery bifurcations from CTA data. Proceedings of SPIE, 2008, , .	0.8	8
743	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics, 2010, 20, 544-552.	0.7	8
744	How to reduce the incidence of contrast induced acute kidney injury after cardiac (invasive) procedures, a review and practical recommendations. Current Medical Research and Opinion, 2011, 27, 1347-1357.	0.9	8
745	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. PLoS ONE, 2014, 9, e111156.	1.1	8
746	In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study. Atherosclerosis, 2014, 235, 58-64.	0.4	8
747	Fine mapping the CETP region reveals a common intronic insertion associated to HDL-C. Npj Aging and Mechanisms of Disease, 2015, 1, 15011.	4.5	8
748	The protective role of Toll-like receptor 3 and type-I interferons in the pathophysiology of vein graft disease. Journal of Molecular and Cellular Cardiology, 2018, 121, 16-24.	0.9	8
749	Repeat variations in polyglutamine diseaseâ€“associated genes and cognitive function in old age. Neurobiology of Aging, 2019, 84, 236.e17-236.e28.	1.5	8
750	The APOE<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>â^—</mml:mo></mml:mrow></mml:msup></mml:math>3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis. Journal of Diabetes Research, 2019, 2019, 1-13.	1.0	8
751	The association between leptin concentration and blood coagulation: Results from the NEO study. Thrombosis Research, 2020, 188, 44-48.	0.8	8
752	Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. Thrombosis Journal, 2021, 19, 45.	0.9	8
753	Estimated pulse wave velocity (ePWV) as a potential gatekeeper for MRI-assessed PWV: a linear and deep neural network based approach in 2254 participants of the Netherlands Epidemiology of Obesity study. International Journal of Cardiovascular Imaging, 2022, 38, 183-193.	0.7	8
754	Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response. JACC Basic To Translational Science, 2020, 5, 1228-1239.	1.9	8
755	Asymmetric Dimethylarginine (ADMA) Levels Display a Morning Peak in Patients with Acute Myocardial Infarction. Disease Markers, 2011, 30, 245-252.	0.6	8
756	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. Atherosclerosis Supplements, 2020, 42, e65-e71.	1.2	8

#	Article	IF	Citations
757	Malignant Right Coronary Artery Anomaly Detected by Magnetic Resonance Coronary Angiography. Circulation, 2002, 106, 1881-1882.	1.6	7
758	Coronary Stent Imaging with Multidetector Row Computed Tomography. International Journal of Cardiovascular Imaging, 2004, 20, 341-344.	0.2	7
759	Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty. Catheterization and Cardiovascular Interventions, 2005, 65, 478-483.	0.7	7
760	Evaluation of Saphenous Vein Coronary Artery Bypass Graft Flow by Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 2005, 7, 631-637.	1.6	7
761	Estimating effects of rare haplotypes on failure time using a penalized Cox proportional hazards regression model. BMC Genetics, 2008, 9, 9.	2.7	7
762	Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients. International Journal of Cardiology, 2008, 124, 166-171.	0.8	7
763	Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin. Atherosclerosis, 2011, 215, 125-129.	0.4	7
764	Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2). American Journal of Cardiology, 2011, 107, 1639-1643.	0.7	7
765	Pharmacogenetics of antiplatelet therapy: ready for clinical application?. Heart, 2011, 97, 1268-1276.	1.2	7
766	How to reduce sudden cardiac death in patients with renal failure. Heart, 2012, 98, 335-341.	1.2	7
767	Potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands. Netherlands Heart Journal, 2012, 20, 197-201.	0.3	7
768	Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. Pharmacogenomics Journal, 2013, 13, 318-324.	0.9	7
769	Associations of atherosclerosis in the descending thoracic aorta on CTA with arterial stiffness and chronic kidney disease in asymptomatic patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2014, 30, 1151-1159.	0.7	7
770	Appropriate use criteria for optical coherence tomography guidance in percutaneous coronary interventions. Netherlands Heart Journal, 2018, 26, 473-483.	0.3	7
771	Electrocardiographic Detection of Left Ventricular Hypertrophy; Adding Body Mass Index and Spatial QRS-T Angle: A Cross-Sectional Study. Cardiology and Therapy, 2019, 8, 345-356.	1.1	7
772	Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. Cardiology and Therapy, 2019, 8, 29-41.	1.1	7
773	Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Mayo Clinic Proceedings, 2020, 95, 12-14.	1.4	7
774	Ventricular Repolarization is Associated with Cognitive Function, but Not with Cognitive Decline and Brain Magnetic Resonance Imaging (MRI) Measurements in Older Adults. Journal of Clinical Medicine, 2020, 9, 911.	1.0	7

#	Article	IF	Citations
775	Microvascular differences in individuals with obesity at risk of developing cardiovascular disease. Obesity, 2021, 29, 1439-1444.	1.5	7
776	Mendelian randomization study of the relation between adiponectin and heart function, unravelling the paradox. Peptides, 2021, 146, 170664.	1.2	7
777	Micro stent,â„¢ quantitative coronary angiography, and procedural results. , 1996, 38, 135-143.		6
778	Clinical and Angiographic Outcome of Micro Stent II Implantation in Native Coronary Arteries. American Journal of Cardiology, 1998, 81, 152-157.	0.7	6
779	Functional significance of stenoses in coronary artery bypass grafts. Journal of the American College of Cardiology, 2004, 44, 1877-1882.	1.2	6
780	Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. Journal of Internal Medicine, 2008, 264, 571-585.	2.7	6
781	Metabolic Background Determines the Importance ofNOS3Polymorphisms in Restenosis after Percutaneous Coronary Intervention: A Study in Patients with and without the Metabolic Syndrome. Disease Markers, 2009, 26, 75-83.	0.6	6
782	Relation Between Framingham Risk Categories and the Presence of Functionally Relevant Coronary Lesions as Determined on Multislice Computed Tomography and Stress Testing. American Journal of Cardiology, 2009, 104, 758-763.	0.7	6
783	Head-to-head comparison between bicycle exercise testing and coronary calcium score and coronary stenoses on multislice computed tomography. Coronary Artery Disease, 2009, 20, 281-287.	0.3	6
784	Fingertip digital thermal monitoring: a fingerprint for cardiovascular disease?. International Journal of Cardiovascular Imaging, 2010, 26, 249-252.	0.7	6
785	Variation in the CBP gene involved in epigenetic control associates with cognitive function. Neurobiology of Aging, 2011, 32, 549.e1-549.e8.	1.5	6
786	Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current Medical Research and Opinion, 2012, 28, 203-211.	0.9	6
787	Hypertension in developing countries. Lancet, The, 2012, 380, 1471-1472.	6.3	6
788	Aspiration Thrombectomy During Primary Percutaneous Coronary Intervention as Adjunctive Therapy to Early (inâ€ambulance) Abciximab Administration in Patients with Acute ST Elevation Myocardial Infarction: An Analysis from Leiden MISSION! Acute Myocardial Infarction Treatment Optimization Program. Journal of Interventional Cardiology, 2012, 25, 1-9.	0.5	6
789	High coronary plaque load: a heavy burden. European Heart Journal, 2013, 34, 3168-3170.	1.0	6
790	The Use of Intra-aortic Balloon Pump in a Real-World Setting: A Comparison between Survivors and Nonsurvivors from Acute Coronary Syndrome Treated with IABP. The Jakarta Acute Coronary Syndrome Registry. International Journal of Angiology, 2013, 22, 213-222.	0.2	6
791	Increased Platelet Reactivity Is Associated with Circulating Platelet-Monocyte Complexes and Macrophages in Human Atherosclerotic Plaques. PLoS ONE, 2014, 9, e105019.	1.1	6
792	Candidate Gene Analysis of Mortality in Dialysis Patients. PLoS ONE, 2015, 10, e0143079.	1.1	6

#	Article	IF	Citations
793	Association between changes in brain microstructure and cognition in older subjects at increased risk for vascular disease. BMC Neurology, 2015, 15, 133.	0.8	6
794	Echocardiographic associates of atrial fibrillation in end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 32, gfw352.	0.4	6
795	A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on Highâ€Sensitivity Cardiac Troponinâ€I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology and Therapeutics, 2018, 104, 311-316.	2.3	6
796	A critical appraisal of pharmacogenetic inference. Clinical Genetics, 2018, 93, 498-507.	1.0	6
797	Chest pain in the absence of obstructive coronary artery disease. International Journal of Cardiology, 2019, 280, 19-28.	0.8	6
798	Indications for an early invasive strategy in NSTE-ACS patients. Netherlands Heart Journal, 2020, 28, 131-135.	0.3	6
799	Genetics and Not Shared Environment Explains Familial Resemblance in Adult Metabolomics Data. Twin Research and Human Genetics, 2020, 23, 145-155.	0.3	6
800	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEYÂOUTCOMES. Journal of the American College of Cardiology, 2020, 75, 448-451.	1.2	6
801	Interplay of circulating leptin and obesity in cognition and cerebral volumes in older adults. Peptides, 2021, 135, 170424.	1.2	6
802	Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation for acute myocardial infarction on coronary plaque composition at nine months follow-up: a Virtual Histology intravascular ultrasound analysis. Results from the Leiden MISSION! intervention study. EuroIntervention, 2009, 5, 565-572.	1.4	6
803	The Influence of Angiographic Endpoints on the Outcome of Lipid Intervention Studies. Angiology, 1996, 47, 633-642.	0.8	5
804	End-diastolic and end-systolic volume from the left ventricular angiogram: how accurate is visual frame selection? Comparison between visual and semi-automated comnputer-assisted analysis. International Journal of Cardiovascular Imaging, 2003, 19, 259-266.	0.2	5
805	Novel clinical applications of state-of-the-art multi-slice computed tomography. International Journal of Cardiovascular Imaging, 2009, 25, 241-254.	0.7	5
806	Matrix Metalloproteinases 2 and 3 Gene Polymorphisms and the Risk of Target Vessel Revascularization after Percutaneous Coronary Intervention: Is There Still Room for Determining Genetic Variation of MMPs for Assessment of an Increased Risk of Restenosis?. Disease Markers, 2010, 29, 265-273.	0.6	5
807	100ÂkV versus 120ÂkV: effective reduction in radiation dose?. International Journal of Cardiovascular Imaging, 2011, 27, 587-591.	0.7	5
808	Fractional Flow Reserve Is Not Associated with Inflammatory Markers in Patients with Stable Coronary Artery Disease. PLoS ONE, 2012, 7, e46356.	1.1	5
809	Comparison of Lipid Profiles and Attainment of Lipid Goals in Patients <65 Years Versus Patients â‰¥65 Years (from the Lipid Treatment Assessment Project [L-TAP] 2). American Journal of Cardiology, 2012, 109, 1738-1742.	0.7	5
810	320-row CT scanning: reduction in tube current parallels reduction in radiation exposure?. International Journal of Cardiovascular Imaging, 2012, 28, 193-197.	0.7	5

#	Article	IF	Citations
811	Echocardiographical determinants of an abnormal spatial QRS-T angle in chronic dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 3045-3052.	0.4	5
812	Changes in ischaemia as assessed with single-photon emission computed tomography myocardial perfusion imaging in high-risk patients with diabetes without cardiac symptoms: relation with coronary atherosclerosis on computed tomography coronary angiography. European Heart Journal Cardiovascular Imaging, 2015, 16, 863-870.	0.5	5
813	Blood Leukocyte Count on Admission Predicts Cardiovascular Events in Patients with Acute Non-ST Elevation Myocardial Infarction. International Journal of Angiology, 2015, 24, 127-132.	0.2	5
814	Classical determinants of coronary artery disease as predictors of complexity of coronary lesions, assessed with the SYNTAX score. Netherlands Heart Journal, 2017, 25, 490-497.	0.3	5
815	Relation of Overall and Abdominal Adiposity With Electrocardiogram Parameters of Subclinical Cardiovascular Disease in Individuals Aged 45 to 65 Years (from the Netherlands Epidemiology of) Tj ETQq1 1 0.784314 rgBT /Overlock	4.1	5
816	Prognostic Importance of Increased Right Ventricular Afterload in Orthotopic Liver Transplantation Recipients With Endstage Cirrhosis. Heart Lung and Circulation, 2019, 28, 893-900.	0.2	5
817	Cognitive Function in Dementia-Free Subjects and Survival in Old Age: The PROSPER Study. American Journal of Medicine, 2019, 132, 1466-1474.e4.	0.6	5
818	Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Cardiology and Therapy, 2019, 8, 55-67.	1.1	5
819	Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. Journal of Clinical Medicine, 2020, 9, 3249.	1.0	5
820	Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused postâ€ischaemic inflammatory response. Journal of Cellular and Molecular Medicine, 2021, 25, 7772-7782.	1.6	5
821	Prognostic Value of Natriuretic Peptides for All-Cause Mortality, Right Ventricular Failure, Major Adverse Events, and Myocardial Recovery in Advanced Heart Failure Patients Receiving a Left Ventricular Assist Device: A Systematic Review. Frontiers in Cardiovascular Medicine, 2021, 8, 699492.	1.1	5
822	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.3	5
823	Comparison of MSCT and MRA in the Evaluation of an Anomalous Right Coronary Artery. Journal of Cardiovascular Magnetic Resonance, 2003, 5, 403-405.	1.6	5
824	Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, CIRCGEN121003460.	1.6	5
825	Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial. British Heart Journal, 2001, 86, 533-539.	2.2	4
826	Secondary prevention in coronary heart disease patients with low HDL: which options do we have?. International Journal of Cardiology, 2003, 90, 15-21.	0.8	4
827	Transcardiac conductance for continuous measurement of left ventricular volume: validation vs. angiography in patients. Intensive Care Medicine, 2004, 30, 1370-1376.	3.9	4
828	Advances in the noninvasive evaluation of coronary artery disease with multislice computed tomography. Expert Review of Medical Devices, 2006, 3, 441-451.	1.4	4

#	Article	IF	Citations
829	Atherosclerotic plaque imaging by PET/CT; can inactive, active and mixed plaques be discerned?. International Journal of Cardiovascular Imaging, 2009, 25, 141-144.	0.7	4
830	Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1. Chronobiology International, 2009, 26, 637-652.	0.9	4
831	Ten-year mortality risk of patients undergoing elective PCI: long-term follow-up of the GENetic Determinants of Restenosis (GENDER) study. Netherlands Heart Journal, 2013, 21, 101-105.	0.3	4
832	Thrombus management in the catheterisation laboratory in the setting of primary percutaneous coronary intervention: what is the current evidence?. Heart, 2013, 99, 279-284.	1.2	4
833	Research ethics needs fine tuning, not rigidity: how to promote evidence in neglected patient populations by rethinking informed consent: Figure 1. European Heart Journal, 2015, 36, 2681-2685.	1.0	4
834	Treatment variation in stent choice in patients with stable or unstable coronary artery disease. Netherlands Heart Journal, 2016, 24, 110-119.	0.3	4
835	Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide. European Journal of Preventive Cardiology, 2016, 23, 1104-1113.	0.8	4
836	Association of fasting triglyceride concentration and postprandial triglyceride response with the carotid intima-media thickness in the middle aged: The Netherlands Epidemiology of Obesity study. Journal of Clinical Lipidology, 2017, 11, 377-385.e1.	0.6	4
837	Body fat distribution, in particular visceral fat, is associated with cardiometabolic risk factors in women with obesity. Atherosclerosis, 2017, 263, e175.	0.4	4
838	Guide extension catheter stepwise advancement facilitated by repeated distal balloon anchoring. Cardiovascular Revascularization Medicine, 2017, 18, 66-69.	0.3	4
839	Associations between normal range albuminuria, renal function and cardiovascular function in a population-based imaging study. Atherosclerosis, 2018, 272, 94-100.	0.4	4
840	Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry. Pharmacogenomics Journal, 2020, 20, 482-493.	0.9	4
841	Association of High-Density Lipoprotein Cholesterol With Cognitive Function: Findings From the PROspective Study of Pravastatin in the Elderly at Risk. Journal of Aging and Health, 2020, 32, 1267-1274.	0.9	4
842	P300/CBP Associated Factor (PCAF) Deficiency Enhances Diet-Induced Atherosclerosis in ApoE3*Leiden Mice via Systemic Inhibition of Regulatory T Cells. Frontiers in Cardiovascular Medicine, 2020, 7, 604821.	1.1	4
843	The impact of transvenous cardioverter-defibrillator implantation on quality of life, depression and optimism in dialysis patients: report on the secondary outcome of QOL in the randomized controlled ICD2 trial. Quality of Life Research, 2021, 30, 1605-1617.	1.5	4
844	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. Circulation Genomic and Precision Medicine, 2021, 14, e003219.	1.6	4
845	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. International Journal of Cardiology, 2021, 334, 10-17.	0.8	4
846	Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile. Atherosclerosis, 2021, 328, 144-152.	0.4	4

#	Article	IF	Citations
847	Post-intervention IVUS is not predictive for very late in-stent thrombosis in drug-eluting stents. Acta Cardiologica, 2009, 64, 611-616.	0.3	4
848	Cold-Inducible RNA-Binding Protein but Not Its Antisense lncRNA Is a Direct Negative Regulator of Angiogenesis In Vitro and In Vivo via Regulation of the 14q32 angiomiRsâ€"microRNA-329-3p and microRNA-495-3p. International Journal of Molecular Sciences, 2021, 22, 12678.	1.8	4
849	Assessment of parallel conductance for the trans-cardiac conductance method: can we use the hypertonic saline method with pulmonary artery injections?. Physiological Measurement, 2004, 25, 565-576.	1.2	3
850	Dynamic Multislice Computed Tomography of Left Ventricular Function. Circulation, 2004, 109, e25-6.	1.6	3
851	Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease: Response to Cicero et al.. Diabetes Care, 2005, 28, 1263-1264.	4.3	3
852	Lipoprotein (a) and risk of cardiovascular disease in patients with metabolic syndrome in a population of familial hypercholesterolaemia. Journal of Internal Medicine, 2006, 260, 183-185.	2.7	3
853	Determinants of CRP level in statin-treated patients. Current Medical Research and Opinion, 2008, 24, 1065-1068.	0.9	3
854	The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents. Heart and Vessels, 2011, 26, 235-241.	0.5	3
855	Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. Cor Et Vasa, 2012, 54, e32-e38.	0.1	3
856	4C.03. Journal of Hypertension, 2015, 33, e57.	0.3	3
857	Genetic risk scoresâ€"new promises for drug evaluation. Nature Reviews Cardiology, 2015, 12, 321-322.	6.1	3
858	Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention. Thrombosis and Haemostasis, 2016, 115, 353-360.	1.8	3
859	Is Hepatic Triglyceride Content Associated with Aortic Pulse Wave Velocity and Carotid Intima-Media Thickness? The Netherlands Epidemiology of Obesity Study. Radiology, 2017, 285, 73-82.	3.6	3
860	Subclinical thyroid dysfunction and depressive symptoms: protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies. BMJ Open, 2019, 9, e029716.	0.8	3
861	CD8+ T Cells Protect During Vein Graft Disease Development. Frontiers in Cardiovascular Medicine, 2019, 6, 77.	1.1	3
862	Prediction Power on Cardiovascular Disease of Neuroimmune Guidance Cues Expression by Peripheral Blood Monocytes Determined by Machine-Learning Methods. International Journal of Molecular Sciences, 2020, 21, 6364.	1.8	3
863	Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. International Journal of Cardiology, 2020, 318, 7-13.	0.8	3
864	Common Genetic Variation in MC4R Does Not Affect Atherosclerotic Plaque Phenotypes and Cardiovascular Disease Outcomes. Journal of Clinical Medicine, 2021, 10, 932.	1.0	3

#	Article	IF	Citations
865	Identification of a novel proinsulin-associated SNP and demonstration that proinsulin is unlikely to be a causal factor in subclinical vascular remodelling using Mendelian randomisation. Atherosclerosis, 2017, 266, 196-204.	0.4	3
866	Gated SPECT in left bundle branch block: from improved diagnosis to improved treatment. International Journal of Cardiovascular Imaging, 2009, 25, 53-55.	0.7	2
867	CT perfusion angiography; beware of artifacts!. International Journal of Cardiovascular Imaging, 2010, 26, 355-358.	0.7	2
868	Late stent malapposition: innocent phenomenon or major risk marker? reply. European Heart Journal, 2010, 31, 260-261.	1.0	2
869	IVUS detects more coronary calcifications than MSCT; matter of both resolution and cross-sectional assessment?. International Journal of Cardiovascular Imaging, 2011, 27, 1011-1014.	0.7	2
870	Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis. Biomarkers in Medicine, 2012, 6, 53-66.	0.6	2
871	Reduction of radiation dose using 80ÂkV tube voltage: a feasible strategy?. International Journal of Cardiovascular Imaging, 2012, 28, 425-428.	0.7	2
872	Communicating risk to patients in the emergency department. BMJ, The, 2016, 355, i6437.	3.0	2
873	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. Journal of the American College of Cardiology, 2017, 69, 153.	1.2	2
874	Lower Performance in Orientation to Time and Place Associates with Greater Risk of Cardiovascular Events and Mortality in the Oldest Old: Leiden 85-Plus Study. Frontiers in Aging Neuroscience, 2017, 9, 307.	1.7	2
875	The mortality benefit seen with the newer more potent oral P2Y12 inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis. Cor Et Vasa, 2018, 60, e127-e132.	0.1	2
876	Association of diastolic blood pressure with cardiovascular events in older people varies upon cardiovascular history. Journal of Hypertension, 2018, 36, 773-778.	0.3	2
877	Association of complement receptor 1 gene polymorphisms with cognitive function. Physiological Genomics, 2018, 50, 102-103.	1.0	2
878	LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: A mendelian randomization analysis. Atherosclerosis, 2018, 275, e4.	0.4	2
879	Relationship between coronary artery calcification and myocardial ischemia on computed tomography myocardial perfusion in patients with stable chest pain. Journal of Nuclear Cardiology, 2021, 28, 1707-1714.	1.4	2
880	Borderline Q-waves in individuals without overt cardiovascular disease: Relations with adiposity, subclinical atherosclerosis and vascular stiffness. International Journal of Cardiology, 2019, 274, 331-336.	0.8	2
881	The role of insulin resistance in the relation of visceral, abdominal subcutaneous and total body fat to cardiovascular function. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2230-2241.	1.1	2
882	Genome-wide Association Study of the Postprandial Triglyceride Response Yields Common Genetic Variation in Hepatic Lipase (LIPC). Circulation Genomic and Precision Medicine, 2020, 13, e002693.	1.6	2

#	Article	IF	Citations
883	Quantification of myocardial ischemia and subtended myocardial mass at adenosine stress cardiac computed tomography: a feasibility study. International Journal of Cardiovascular Imaging, 2021, 37, 3313-3322.	0.7	2
884	M.542 LDL-C/HDL-C ratio in patients with coronary artery disease and low HDL-C: The radar study. Atherosclerosis, 2004, 5, 125-126.	0.4	2
885	Toll-Like Receptor Induced CD11b and L-Selectin Response in Patients with Coronary Artery Disease. PLoS ONE, 2013, 8, e60467.	1.1	2
886	PCSK9 inhibition in high-risk patients. Aging, 2019, 11, 10791-10792.	1.4	2
887	The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients. Endocrine Connections, 2020, 9, 55-62.	0.8	2
888	On the statistical modelling of coronary arteriographic data: dynamics of coronary atherosclerosis related to systemic and focal parameters. , 1997, 16, 2829-2841.		1
889	Discrimination between pericardial disease and myocardial disease using tissue Doppler imaging in a patient with right-sided heart failure and multiple myeloma. International Journal of Cardiovascular Imaging, 2003, 19, 1-4.	0.2	1
890	Coronary artery calcium screening: sufficient evidence for accurate risk assessment?. International Journal of Cardiovascular Imaging, 2008, 24, 907-909.	0.7	1
891	Statins and Blood Pressure. Archives of Internal Medicine, 2008, 168, 2383.	4.3	1
892	CT angiography; useful in non-selected outpatients?. International Journal of Cardiovascular Imaging, 2009, 25, 315-318.	0.7	1
893	CT angiography; no collateral damage. International Journal of Cardiovascular Imaging, 2009, 25, 339-342.	0.7	1
894	Distal protection beneficial?. International Journal of Cardiovascular Imaging, 2010, 26, 135-138.	0.7	1
895	Functional analysis by 64-slice CT scanning: prediction of left ventricular dysfunction together with reduction in radiation exposure?. International Journal of Cardiovascular Imaging, 2011, 27, 1089-1093.	0.7	1
896	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs, 2011, 16, 203-233.	1.0	1
897	320-row CT: does beat-to-beat motion of the coronary arteries affect image quality?. International Journal of Cardiovascular Imaging, 2012, 28, 147-151.	0.7	1
898	RP105 (cd180) as a TLR-4 regulator ameliorates atherosclerosis via its role on B-cells. European Heart Journal, 2013, 34, P2389-P2389.	1.0	1
899	Impact of Timing of Eptifibatide Administration on Preprocedural Infarct-Related Artery Patency in Acute STEMI Patients Undergoing Primary PCI. International Journal of Angiology, 2014, 23, 207-214.	0.2	1
900	Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice. Atherosclerosis, 2014, 235, e19.	0.4	1

#	Article	IF	Citations
901	Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment. Family Practice, 2015, 32, 646-651.	0.8	1
902	The APOE*3Leiden.GK +/- mouse as novel translational model for dyslipidemia, type 2 diabetes and macrovascular complications. Atherosclerosis, 2016, 252, e226-e227.	0.4	1
903	PROGNOSTIC IMPLICATIONS OF LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN IN STAGE 4 AND 5 CHRONIC KIDNEY DISEASE PATIENTS. Journal of the American College of Cardiology, 2017, 69, 1459.	1.2	1
904	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome. Netherlands Heart Journal, 2017, 25, 655-663.	0.3	1
905	Characterization of the left ventricular arrhythmogenic substrate with multimodality imaging: role of innervation imaging and left ventricular global longitudinal strain. European Journal of Hybrid Imaging, 2019, 3, 14.	0.6	1
906	REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL. Journal of the American College of Cardiology, 2019, 73, 4.	1.2	1
907	Triple Treatment With Alirocumab And Evinacumab On Top Of Atorvastatin Regresses Lesion Size And Improves Plaque Phenotype In Apoe*3leiden.Cetp Mice. Atherosclerosis, 2019, 287, e12.	0.4	1
908	Myocardial infarction patients referred to the primary care physician after 1â€'year treatment according to aÂguideline-based protocol have aÂgood prognosis. Netherlands Heart Journal, 2019, 27, 550-558.	0.3	1
909	Associations of metabolomic profiles with circulating vitamin E and urinary vitamin E metabolites in middle-aged individuals. Nutrition, 2022, 93, 111440.	1.1	1
910	COVID-19 associated perimyocarditis. Magnetic Resonance Imaging, 2021, 84, 132-134.	1.0	1
911	1.P.43 A hepatic lipase promoter polymorphism (C-480T) abolishes insulin-sensitivity of hepatic lipase expression. Atherosclerosis, 1997, 134, 25.	0.4	0
912	Noninvasive evaluation of coronary artery disease: magnetic resonance imaging & multi-slice computed tomography. Future Cardiology, 2005, 1, 79-86.	0.5	0
913	W01-O-003 Macrophage cathepsin s deficiency attenuates collagen deposition and macrophage apoptosis in advanced atherosclerotic lesions. Atherosclerosis Supplements, 2005, 6, 2.	1.2	0
914	W09-O-003 Tumor necrosis factor-alpha plays a. Atherosclerosis Supplements, 2005, 6, 39-40.	1.2	0
915	We-P11:215 The thromboxane receptor antagonist S 18886 (Terutroban) favored atherosclerosis regression in APOE*3 Leiden transgenic mice. Atherosclerosis Supplements, 2006, 7, 393.	1.2	0
916	Mo-P4:236 Rantes is transiently raised in patients with unstable angina pectoris. Atherosclerosis Supplements, 2006, 7, 98.	1.2	0
917	Th-W60:4 Increased atherosclerotic burden in young versus aged LDL-receptor knockout mice. Atherosclerosis Supplements, 2006, 7, 487.	1.2	0
918	ID: 135 Products of limited elastase/cathepsin G degradation of fibrinogen as new biomarker in cardiovascular disease.. Journal of Thrombosis and Haemostasis, 2006, 4, 88-88.	1.9	0

#	Article	IF	Citations
919	Clinical Applications of Cardiac Multi-Slice Computed Tomography. Current Medical Imaging, 2006, 2, 139-146.	0.4	0
920	Different aspects of coronary artery disease. Netherlands Heart Journal, 2007, 15, 247-247.	0.3	0
921	DUAL PPAR-ALPHA/GAMMA AGONIST TESAGLITAZAR BLOCKS PROGRESSION OF PRE-EXISTING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP TRANSGENIC MICE. Atherosclerosis Supplements, 2008, 9, 209.	1.2	0
922	CT blurring induced bias of quantitative in-stent restenosis analyses. Proceedings of SPIE, 2008, , .	0.8	0
923	Non-significant left main disease; truly non-significant?. International Journal of Cardiovascular Imaging, 2009, 25, 439-442.	0.7	0
924	Cardiac magnetic resonance imaging in primary PCI: additional value?. International Journal of Cardiovascular Imaging, 2009, 25, 643-645.	0.7	0
925	Early Systemic Inflammatory Response to Drug-Eluting Stents Implantation: The Heart of the Difference?. Cardiovascular Drugs and Therapy, 2009, 23, 103-105.	1.3	0
926	PCV107 ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH SIMVASTATIN FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA. Value in Health, 2009, 12, A333.	0.1	0
927	Genetics of ACS and recurrent MI/cardiac death: are we getting to the heart of the (atherosclerotic) matter?. European Heart Journal, 2010, 31, 1038-1040.	1.0	0
928	Validation of a Comprehensive Model of Atherosclerosis for Risk Stratification with Non-Invasive Computed Tomography Coronary Angiography. Heart Lung and Circulation, 2010, 19, S204-S205.	0.2	0
929	W9 LIPID GOAL ATTAINMENT IN EUROPEAN ADULTS WITH DYSLIPIDAEMIA: AN ANALYSIS OF THE LIPID TREATMENT ASSESSMENT PROJECT (L-TAP) 2. Atherosclerosis Supplements, 2010, 11, 2.	1.2	0
930	P70 THE EFFECT OF ALISKIREN ON ATHEROSCLEROSIS DEVELOPMENT IN APOE*3LEIDEN.CETP TRANSGENIC MICE WITH AND WITHOUT TREATMENT WITH ATORVASTATIN. Atherosclerosis Supplements, 2010, 11, 31.	1.2	0
931	365 RECOMBINANT ANTI-PHOSPHORYLCHOLINE IGG ANTIBODIES PREVENT POST-INTERVENTIONAL ACCELERATED ATHEROSCLEROTIC VASCULAR REMODELING. Atherosclerosis Supplements, 2011, 12, 78.	1.2	0
932	Republished: How to reduce sudden cardiac death in patients with renal failure. Postgraduate Medical Journal, 2012, 88, 418-424.	0.9	0
933	Will the interplay between genetic markers for risk factors for a disease and the disease itself bring genetics closer to clinical practice? Great expectations. European Heart Journal, 2012, 33, 290-291.	1.0	0
934	Republished article: Pharmacogenetics of antiplatelet therapy: ready for clinical application?. Postgraduate Medical Journal, 2012, 88, 176-184.	0.9	0
935	TCT-344 Importance of Optimal Reperfusion in Diabetic Patients Treated with Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, B97-B98.	1.2	0
936	Spontaneous plaque disruptions, dissection, erosion and intraplaque hemorrhage in murine vein grafts can be attenuated by TIMP-1 overexpression. Vascular Pharmacology, 2012, 56, 341-342.	1.0	0

#	Article	IF	Citations
937	Statins work around the world. Current Medical Research and Opinion, 2013, 29, 747-749.	0.9	0
938	No genetic determinants of differential cardiovascular event reduction by pravastatin in the PROSPER/PHASE study. European Heart Journal, 2013, 34, 139-139.	1.0	0
939	Visceral fat is stronger associated with electrocardiographic measures of sympathetic activation than subcutaneous fat in individuals with structurally normal hearts: the NEO study. European Heart Journal, 2013, 34, P729-P729.	1.0	0
940	Antiplatelet therapy in acute coronary syndrome: current status and future directions. European Heart Journal Supplements, 2014, 16, C1-C1.	0.0	0
941	A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatide: The X-MAN (Xience vs. Multi-Link Stent in Acute) Tj ETQq1 1 0.784314 rgBT /Ove	0.2	0
942	TROPONIN T IS A STRONG MARKER FOR CARDIOVASCULAR DISEASE IN DIALYSIS PATIENTS, DESPITE HIGH BACKGROUND LEVELS OF SERUM TROPONIN T. Journal of the American College of Cardiology, 2014, 63, A1545.	1.2	0
943	AB0086â€…Anti-Citrullinated Protein Antibodies in Patients with Cardiovascular Disease without RA. Annals of the Rheumatic Diseases, 2016, 75, 926.1-926.	0.5	0
944	Plasma CETP is derived from hepatic kupffer cells rather than adipose tissue. Atherosclerosis, 2016, 252, e244.	0.4	0
945	Quaking post-transcriptionally promotes differentiation of monocytes into pro-atherogenic macrophages by controling pre-mRNA splicing and gene expression. Atherosclerosis, 2016, 252, e256.	0.4	0
946	Affitope-based anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) vaccine (AT04A) reduces atherosclerosis in APOE*3Leiden.CETP mice. Atherosclerosis, 2016, 252, e253-e254.	0.4	0
947	The role of inflammation in the association between adiposity and subclinical atherosclerosis. Atherosclerosis, 2016, 252, e261.	0.4	0
948	Association of baseline apolipoprotein B and friedewald LDLC with long-term re-infarction in hypertriglyceridemic patients with ST-segment elevation myocardial infarction. Atherosclerosis, 2016, 252, e186.	0.4	0
949	Advantages and disadvantages of unstructured cardiovascular risk factor screening for follow-up in primary care. European Journal of Preventive Cardiology, 2016, 23, 1195-1201.	0.8	0
950	08.18â€…Anti-citrullinated protein antibodies: a marker of cardiovascular disease and mortality in patients without rheumatoid arthritis. , 2017, , .		0
951	No association between CETP concentration and intima media thickness in the general population: The Neo study. Atherosclerosis, 2017, 263, e74.	0.4	0
952	Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice. Atherosclerosis, 2017, 263, e29-e30.	0.4	0
953	Metabolic syndrome is associated with electrocardiographic markers of subclinical cardiovascular disease. Atherosclerosis, 2017, 263, e92.	0.4	0
954	MILANO-PILOT: will infusing HDL mimetics containing apoA-imilano continue to regress coronary atherosclerosis in the modern era of intensive statin therapy?. Atherosclerosis, 2017, 263, e11.	0.4	0

#	Article	IF	Citations
955	Very Long-Term Follow-Up After Coronary Rotational Atherectomy: A Single-Center Experience. Angiology, 2017, 68, 519-527.	0.8	0
956	Response to Ciuculete et al. Clinical Genetics, 2017, 92, 565-565.	1.0	0
957	Body fat distribution and genetic variants are associated with sex differences in serum leptin and adiponectin concentrations. Atherosclerosis, 2018, 275, e173.	0.4	0
958	Genetically-determined CETP concentration decreases large HDL and increases small VLDL without affecting LDL. Atherosclerosis, 2018, 275, e25.	0.4	0
959	Common Genetic Variation In Hepatic Lipase (Lipc) Associated With Postprandial Lipid Metabolism In A Genome-Wide Association And Metabolomics Study. Atherosclerosis, 2019, 287, e70.	0.4	0
960	Response by Timal and Jukema to Letter Regarding Article, â€œRandom Controlled Trials of Sudden Cardiac Death: Use of Autopsy to Refine Sudden Cardiac Death Outcomesâ€• Circulation, 2019, 140, e744-e745.	1.6	0
961	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2019, 73, 2034.	1.2	0
962	Reply. Journal of the American College of Cardiology, 2020, 75, 241.	1.2	0
963	A case of tortuous anatomy: cervical aortic arch. European Heart Journal, 2021, 42, 1811-1811.	1.0	0
964	METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL. Journal of the American College of Cardiology, 2021, 77, 150.	1.2	0
965	Differential insulin sensitivity of NMR-based metabolomic measures in a two-step hyperinsulinemic euglycemic clamp study. Metabolomics, 2021, 17, 57.	1.4	0
966	Higher thyroid stimulating hormone leads to cardiovascular disease and an unfavorable lipid profile: EVidence from multi-cohort Mendelian randomization and metabolomic profiling. Atherosclerosis, 2021, 331, e40.	0.4	0
967	Dietary-derived antioxidants do not decrease the risk of ischemic stroke: A Mendelian randomization study. Atherosclerosis, 2021, 331, e14.	0.4	0
968	Classical risk factors for primary coronary artery disease from an ageing perspective through Mendelian randomization. Atherosclerosis, 2021, 331, e213.	0.4	0
969	Classical cardiovascular risk factors and secondary major coronary events: A Mendelian randomization study in the UK biobank population. Atherosclerosis, 2021, 331, e216-e217.	0.4	0
970	Relative risk of thrombo-embolisms and major bleedings is high in left ventricular assist device patients with unstable anticoagulation control. Atherosclerosis, 2021, 331, e227.	0.4	0
971	Investigating the relationships between unfavorable sleep and metabolomic traits: Evidence from multi-cohort multivariable regression and mendelian randomization analyses. Atherosclerosis, 2021, 331, e42.	0.4	0
972	Fatty acid-induced transcriptomic and methylomic changes in T-cells are involved in immunometabolism. Atherosclerosis, 2021, 331, e110.	0.4	0

#	Article	IF	Citations
973	Differential insulin sensitivity of NMR-based metabolomic measures in a two-step hyperinsulinemic euglycemic clamp study. Atherosclerosis, 2021, 331, e44-e45.	0.4	0
974	800 Current percutaneous transluminal coronary angioplasty practice and results in the Netherlands: insights from the GENDER project. European Heart Journal, 2003, 24, 142.	1.0	0
975	P2945 Four-pixel velocity analysis is the preferential approach in evaluating magnetic resonance velocity maps of coronary artery bypass grafts. European Heart Journal, 2003, 24, 569.	1.0	0
976	2495 Secondary prevention with folic acid: effects on clinical outcomes (GOES study). European Heart Journal, 2003, 24, 469.	1.0	0
977	The Pharmacogenetics of Atherosclerosis. , 2011, , 353-367.		0
978	How should future angiographic trials be designed?. Developments in Cardiovascular Medicine, 1998, , 119-131.	0.1	0
979	Genetic factors in the progression of atherosclerosis and response to cholesterol lowering drugs. Developments in Cardiovascular Medicine, 1998, , 95-100.	0.1	0
980	Thermolabile Methylenetetrahydrofolate Reductase in Coronary Artery Disease. Journal of the American College of Cardiology, 1998, 31, 145A.	1.2	0
981	Raman Spectroscopy Provides Chemical Mappings of Atherosclerotic Plaques in APOE*3 Leiden Transgenic Mice. Journal of the American College of Cardiology, 1998, 31, 500A-501A.	1.2	0
982	Original Research: Long-Term Prognosis After ST-Elevation Myocardial Infarction in Patients with a Prior Cancer Diagnosis. Cardiology and Therapy, 2021, , 1.	1.1	0
983	Inhibition of BMP9 and BMP10 signalling by the ALK1-Fc Ligand Trap enhances systemic inflammation and increases vein graft atherosclerosis. European Heart Journal, 2020, 41, .	1.0	0
984	Normal and reference values for MRI-based pulse wave velocity in the middle-aged general population. European Heart Journal, 2020, 41, .	1.0	0
985	Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES. European Heart Journal, 2020, 41, .	1.0	0
986	Impaired Global Longitudinal Strain Is Associated with Cardiovascular Events in Hodgkin Lymphoma Survivors. Cancers, 2022, 14, 2329.	1.7	0